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Molecular control of dendritic cell development and function 
Colleen M. Lau 
 
 Dendritic cells (DCs) comprise a distinct lineage of potent antigen-presenting mononuclear 
phagocytes that serve as both mediators of innate immune responses and key facilitators of the adaptive 
immune response.  DCs play both immunogenic and tolerogenic roles through their dual ability to elicit 
pathogen-specific T cell immunity as well as induce regulatory T cell (Treg) responses to promote 
tolerance in the steady state. The aim of the work presented here is to examine the normal regulatory 
mechanisms of DC development and function, starting with the dissection of mechanisms behind an 
aberrantly activated developmental pathway, followed by the exploration of new mechanisms governed 
by two candidate transcription factors. The first chapter of the thesis focuses on the growth factor receptor 
Flt3, an essential regulator of normal DC development in both mice and humans, and concurrently one of 
the most commonly mutated proteins found in acute myeloid leukemia (AML). We investigated the effect 
of its most common activating mutation in AML, the Flt3 internal tandem duplication (Flt3-ITD), and found 
that this mutation caused a significant cell-intrinsic expansion of all DC populations. This effect was 
associated with an expansion of Tregs and the ability to dampen self-reactivity, with an inability to control 
autoimmunity in the absence of Tregs. Thus, we describe a potential mechanism by which leukemia can 
modulate T cell responses and support Treg expansion indirectly through DCs, which may compromise 
immunosurveillance and promote leukemogenesis. The subsequent chapters explore the basic molecular 
mechanisms of DC development by using Flt3 expression as a guide to uncover new candidates involved 
in the DC transcriptional program. We show that Myc family transcription factor, Mycl1, is largely 
dispensable for DC development and function, contrary to recent published findings that propose a role in 
proliferation and T cell priming.  On the other hand, we find that conditional deletion of our second 
candidate gene, an Ets family transcription factor, has diverse effects on DC development, monocyte 
homeostasis, and cytokine production. Overall, our studies highlight an unexpected molecular link 
between DC development and leukemogenesis, and elucidate novel mechanisms controlling DC 
differentiation and function. 
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The Immune System 
The human body has developed intricate defense mechanisms that protect the organism from 
any pathogenic assault that it encounters. Replenishment of these immune cells relies on the 
hematopoietic stem cell (HSC), a pluripotent cell that has the ability to give rise to all cells within the 
hematopoietic system, while still maintaining its own populations through the process of self-renewal. By 
using a tightly orchestrated combination of intrinsic programs and environmental communication, the HSC 
gives rise to highly proliferative progeny committed to distinct lineages. These progenitors ultimately 
undergo a series of differentiation events that produces erythrocytes for oxygen transport, platelets for 
blood clotting, and all the leukocytes that make up the immune system. These leukocytes can broadly be 




The innate immune response is a quick, nonspecific, broad-spectrum reaction that comprises 
several layers of defense, the first being physical barriers (like the skin), secretion of antimicrobial 
molecules, and circulating plasma proteins called complement proteins that enhance microbial 
recognition. Hematopoietic cell types that carry out the initiating attacks include phagocytes like 
monocytes, macrophages and granulocytes (neutrophils, eosiniophils, and basophils), as well as 
lymphocytes called natural killer cells (NK cells). Innate immune cells express a number of invariant 
pattern recognition receptors (PRRs) that recognize general microbial components called pathogen-
associated molecular patterns (PAMPS), such as liposaccharides on bacterial cell wall or double-
stranded RNA from viruses1. Recognition by these receptors induces phagocytosis and subsequent killing 
(in the case of macrophages and granulocytes), or initiates cytokine signaling that facilitates recruitment 
of other immune cells1.  NK cells express additional receptors that help them distinguish between healthy 
self and “altered” self by sensing low levels of major histocompatibility complex I (MHC I) or cellular and 
metabolic stress signals2. Activated signaling leads to local release of cytotoxic substances that penetrate 




On the other hand, the adaptive immune response incorporates more refined and precise tactics 
that target specific pathogens. These responses are largely mediated by T cells and B cells, which 
express receptors that recognize specific antigen from a given pathogen. The diversity of T cell and B cell 
receptors generated by random genetic recombination (known as V(D)J recombination) provides a vast 
repertoire of molecules that can recognize virtually any given antigen3. Upon antigen-receptor recognition, 
T cells can mature into CD4+ helper T cells that secrete cytokines to help tailor and orchestrate the 
response, or they can mature into CD8+ cytotoxic T cells that target and kill infected cells4. Meanwhile, B 
cells mature into plasma cells to generate and secrete antigen-specific antibodies that enhance pathogen 
recognition and targeting4. Recognition induces selective expansion of these antigen-specific clones and 
enables robust elimination of the pathogen. More importantly, after clearance, a reservoir of these 
antigen-specific lymphocytes remains and provides for immunological memory, a key phenomenon that 
allows more efficient pathogenic clearance upon re-encounter. Building up this memory is the underlying 
principle behind vaccine therapy5. But to initiate and mount these tactical responses requires prior 
“education” of what these pathogens are, which is a crucial task taken on by a rare population of 
phagocytic innate immune cells called dendritic cells. 
 
Dendritic cells 
Dendritic cells (DCs) were first described by Paul Langerhans in 1868 as novel neurons with 
dendritic morphology in the skin6. Over a century later, work by Ralph Steinman and Zanvil Cohn 
identified DCs from lymphoid organs as a unique cell type with long cytoplasmic projections7 capable of 
potent stimulation of T cells8. The cascade of research that ensued solidified the central role of DCs in 
bridging the innate and adaptive immune responses. Ultimately, this research paved the way for Ralph 
Steinman to receive a Nobel Prize in Physiology or Medicine in 2011. 
With their stellate morphology and long cytoplasmic processes, DCs are specialized at sensing 
and patrolling tissue environments for foreign intrusions. Similar to other phagocytic innate immune cells, 
DCs are enriched in a plethora of PRRs so that they are equipped to detect a wide variety of pathogens. 
These include membrane-bound PRRs like Toll-like receptors (TLRs) and C-type lectin receptors (CLRs), 
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as well as cytoplasmic PRRs like NOD-like receptors (NLRs)9. Collectively, expression of the receptors 
allows DCs to recognize both extracellular and intracellular components of gram-negative and -positive 
bacteria, viruses, fungi, and parasites. Unlike other phagocytic cells, the immediate goal of some DCs is 
not necessarily to take in and kill pathogens. Rather, their primary goal is to alert the adaptive arm of the 
immune system, by processing remnants of the pathogen and presenting this antigen to naïve T cells. For 
this, DCs have acquired unique features and capabilities that duly warrant their designation as  
professional antigen-presenting cells. 
 
DC development 
Years of DC research have established the DC lineage as a unique branch of hematopoiesis, 
however the exact tracing from earliest progenitor to mature DC still remains controversial. DC origins, 
like most hematopoietic cells, start with HSCs in the bone marrow10. Adoptive transfer of common 
myeloid progenitors (CMPs) and common lymphoid progenitors (CLPs) suggests that DCs can have 
either myeloid or lymphoid origin11. However, more recent fate-mapping studies have shown that only a 
minority of DCs seems to be derived from lymphoid progenitors12, suggesting that the majority is actually 
of myeloid origin. In line with this, the macrophage-dendritic cell progenitor (MDP) has been proposed to 
be the first descendent of the CMP with the potential to give rise to DCs, as well as macrophages and 
monocytes13. However, recent clonogenic studies have questioned the DC potential of the MDP14. 
Downstream of the MDP is the common dendritic cell progenitor (CDP), the first DC-restricted progenitor 
capable of generating all DCs in both lymphoid and nonlymphoid tissue. At this stage, lineage bifurcation 
occurs to generate the two main types of DCs: conventional dendritic cells (cDCs) and plasmacytoid DCs 
(pDCs). cDC differentiation occurs via intermediate circulating precursor cells called pre-DCs, which seed 
peripheral tissues to finally differentiate into cDCs. Meanwhile, pDCs continue and complete their 
development in the bone marrow. 
 
Conventional dendritic cells 
The superior ability for antigen presentation by DCs is mostly attributed to cDCs. Of all murine 
tissue cDCs, splenic cDCs have been the most studied and well characterized. Splenic DCs can be 
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readily identified by high expression of ! integrin CD11c and histocompatibility complex MHC class II9. 
They are broadly subcategorized into two groups: CD11b+ (CD8-) cDCs and CD8+ (CD11b-) cDCs. 
CD11b+ cDCs are highly proficient at presenting exogenous antigen on MHC class II molecules and 
activating naïve CD4+ T cells15. Within the spleen, CD11b+ cDCs are mostly found in the marginal zone15, 
an anatomical transit area for blood to enter the main lymphoid regions and consequently a prime location 
to patrol the blood for foreign antigen16. On the other hand, CD8+ cDCs have acquired a specialized 
mechanism called cross-presentation that allows them to present exogenous antigen on MHC class I 
molecules and activate naïve CD8+ T cells17. Within the spleen, CD8+ cDCs are mainly found in the T cell 
zones15. Thus, with their broad expression of sensors, strategic placement, and their collective ability to 
present intracellular and extracellular antigen to any naïve T cell, cDCs are uniquely adept at mounting an 
adaptive immune response. 
Work in recent years has revealed the significant phenotypic and functional heterogeneity that 
exists within these cDC subsets. CD11b+ cDCs consist of two subsets that are developmentally, 
functionally, and phenotypically distinct. More than half of CD11b+ cDCs are cDCs that rely on Notch2 
receptor signaling for late development.  These cDCs are required for optimal priming of CD4+ helper T 
cells, and morphologically and genetically exhibit typical cDC qualities18. The remainder of CD11b+ cDCs 
develops independently of Notch2. These cells appear more monocytic in origin, morphology and 
expression profile, and are more adept at cytokine secretion18. In parallel with CD11b+ cDCs, CD8+ cDCs 
also consist of two divergent groups. Canonical CD8+ cDCs, which also express C-type lectin receptor 
DEC205, are dependent on transcription factor Batf3, secrete IL-12, and possess the unique cross-
presenting abilities that are usually attributed to the CD8+ subset17,19. On the other hand, a smaller but 
significant portion of CD8+ cDCs develops independently of Batf3. The function of these non-canonical 
CD8+ cDCs still remains elusive, as these cells lack the ability to both cross-present and secrete IL-1220. 
Conveniently, these subsets can be readily distinguished by expression of chemokine receptor CX3CR1. 
Specifically, Notch2- and Batf3-dependent subsets express low/negative levels of CX3CR1, while Notch2- 
and Batf3- independent subsets express high levels of CX3CR118,20. These splenic cDC populations are 





Analogous cDC subsets seem to exist in nonlymphoid tissues, although DC subsets in these 
tissues have generally been less characterized. In the intestine, skin, and lung, the functional 
counterparts of canonical CD8+ cDCs are CD103+ (CD11b-) cDCs. Similar to their lymphoid-resident 
equivalent, CD103+ cDCs are dependent on Batf3 and are capable of cross-presentation21-24. 
Conservation of the CD11b+ subset remains less discernable, since these cells display more 
heterogeneity between tissues and are sometimes hard to separate from tissue macrophages or 
monocyte-derived DCs25. Despite this, the small intestine appears to display the most similarity to splenic 
CD11b+ cDC subsets, as CD11b+ CD103+ cDCs are also Notch2-dependent and influence T cell 
differentiation, while CD11b+ CD103- cDCs are Notch2-independent and monocyte-derived18,26. 
 
Plasmacytoid dendritic cells 
Although derived from common origin, pDCs are morphologically and functionally distinct from 
their cDC siblings. Unlike the branched and dendritic shape of cDCs, pDCs exhibit a smaller, rounder, 
more lymphoid morphology, thus appropriating their name as “plasmacytoid” due to their resemblance to 
plasma cells. pDCs are developmentally dependent on transcription factor E2-227, and phenotypically 
express lower levels of CD11c and MHC class II, along with B220, mPDCA-1 (Bst2), and Siglec H9. While 
they are capable of antigen presentation in their activated state, antigen presentation does not seem to 
be their prime function. Instead, pDCs are known for their unrivaled ability to secrete type I interferons, 
primarily mediated by nucleotide sensing through TLR7/TLR9 and adaptor protein MyD8828. Thus, pDCs 


















Cannot cross-present; does not secrete 





Antigen presentation to CD4 T cells Esamhi, CX3CR1lo CD11b+  
Esamlo Notch2-
independent 
Cytokine secretion Esamlo, CX3CR1hi 
 
Table 1. Summary of conventional dendritic cell subtypes within the spleen. 
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promote the activation of various immune cells involved in both the innate and adaptive immune 
responses. Therefore, along with cDCs, pDCs are also important players in bridging the innate and 
adaptive immune responses. 
 
The work presented here aims to explore various aspects of dendritic cell development, function, 
and differentiation by studying established molecular factors and exploring new ones. Chapter 1 focuses 
on growth factor receptor Flt3, a key component of DC development and homeostasis. This study 
investigates the conditions in which Flt3 signaling is aberrantly activated and the consequences that this 
signaling may incur on immunity. Chapter 2 and 3 focuses more on the steady-state, exploring potentially 















THE ROLE OF ACTIVATING FLT3 MUTATIONS IN DENDRITIC CELL 


















Flt3 signaling plays a key role throughout DC development within normal hematopoiesis. But 
among human malignancies, aberrant Flt3 signaling is notoriously associated with tumorigenesis. 
Mutations in the receptor are frequently and selectively found in acute myeloid leukemia (AML), the most 
common being the Flt3 internal tandem duplication (Flt3-ITD). This mutation leads to constitutive activity 
of the Flt3 signal cascade, promoting cell-intrinsic survival and proliferation in the early hematopoietic 
progenitors that actively express Flt3. Many have reported on the role of Flt3-ITD in early hematopoietic 
progenitors, yet no studies have explored its effect on DC development and homeostasis. In this chapter, 
we connect the normal role of Flt3 in DC development with its pathologic role in leukemia. Here we report 
that even a single allele of Flt3-ITD dramatically increased overall DC cell numbers and their progenitors 
in a cell-intrinsic manner. Expression of Flt3-ITD promoted a skewing towards a PD-L1 expressing DC 
population that lacks many hallmarks of the canonical cross-presenting DC, as well as caused a 
downregulation of Flt3 that reduced DC responsiveness to exogenous Flt3 ligand. Along with this, this 
mutation cell-extrinsically expanded the T cell population, with a bias towards more Tregs. We further 
showed that Flt3-ITD dampened the T cell expansion in the graft-versus-host response, and provided 
evidence that the reduced response to self-reactivity was dependent on Tregs. We propose that Flt3-ITD 
may play an early tumor-extrinsic role in leukemogenesis by altering the immunosurveillance mechanisms 




Flt3 in normal hematopoiesis 
 
Flt3 structure 
Fms-like tyrosine kinase 3 (Flt3) belongs to the RTK subclass III family, all of which play 
important roles in cell proliferation, differentiation and survival within hematopoiesis. These other 
receptors include c-Kit, macrophage colony-stimulating factor receptor (M-CSFR), and platelet derived 
growth factor receptors  (PDGFRs)29. Human FLT3 shows about 85% amino acid sequence homology 
with murine Flt329. The receptor is a transmembrane protein that comprises five extracellular 
immunoglobulin-like domains, a transmembrane domain, an intracellular juxtamembrane domain, and two 
intracellular tyrosine kinase domains30. The juxtamembrane domain serves as an autoinhibitory 
mechanism, binding onto the kinase domain until key residues are phosphorylated upon activation to 
release its inhibition31. Activation occurs upon ligand binding, which causes dimerization of the normally 
monomeric receptors32. Autophosphorylation of the cytoplasmic domain follows, which provides docking 
sites for downstream effectors33. 
 
Flt3 ligand 
The ligand for Flt3 was cloned shortly after the cloning of Flt3 and was appropriately named Flt3 
ligand (Flt3L)34,35. Expression of Flt3L is widespread in both murine and human tissues. These tissues 
consist of hematopoietic organs like bone marrow, thymus, blood and spleen, as well as non-
hematopoietic tissues like heart, gonads, lungs, kidneys, intestines, muscle, liver, and placenta29,35,36. 
Three protein isoforms have been identified in mice: the first is a transmembrane isoform with a 
proteolytic cleavage site that produces a soluble protein; the second is a membrane-bound isoform that 
lacks the proteolytic cleavage site, but is anchored to the membrane through a string of hydrophobic 
residues; the third isoform is a soluble protein made up mainly of the extracellular domain37. In humans, 
the transmembrane isoform is most abundant, while in mice, the membrane-bound isoform is the most 
common variant37. All isoforms, however, seem to be biologically active37. The important role of Flt3L in 
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hematopoiesis is apparent in mice that lack the gene. Specifically, severe reductions in numbers are 
found in myeloid and B cell progenitor populations, splenic NK cells, and dendritic cells, concomitant with 
an overall decrease in cellularity38. 
 
Flt3 signal transduction 
Wild-type Flt3 mainly signals through two major pathways: the PI3K/AKT pathway and the 
Ras/MAPK pathway. The former is a key regulator of cell survival and metabolism, while the latter 
provides mitogenic signaling that promotes cell proliferation39. The earliest studies looking at potential 
downstream effectors were performed before the cloning of Flt3L, and thus required the use of chimeric 
receptors to artificially induce activation. Nevertheless, the work established an association with the 
murine Flt3 cytoplasmic domains and major players within the pathways, including PI3K itself and adaptor 
protein Grb2 (associated with the Ras/MAPK pathway), among others29,40,41. Studies conducted after the 
discovery of Flt3L overall agree with the involvement of these two pathways.  For example, interaction 
studies looking at FLT3L-induced activation of human FLT3 also show binding of GRB2, as well as 
transient activation of MAPK42. In addition, FLT3L activation also induces phosphorylation of GAB 
proteins, which are known to interact with both GRB2 and PI3K39,43. It should be noted that signaling 
might differ between species. In particular, murine catalytic domains of Flt3 have been shown to interact 
directly with PI3K, while human FLT3 seems to interact indirectly with PI3K through a complex of 
proteins40,41,44. Furthermore, different cell types may employ these signaling pathways for specific 
functions. For example, within the DC lineage, mTOR of the PI3K pathway has been shown to be an 
important signaling molecule downstream of Flt3L-induced DC development45. 
Activation of the JAK/STAT pathway has also been proposed to occur downstream of 
endogenous Flt3 signaling independently of Jak kinases and Src family kinases46. Specifically, Flt3L-
induced signaling results in phosphorylation of Stat5a in a murine cell line stably transfected with wild-
type human FLT347. Furthermore, murine myeloid progenitors deficient in Stat5a show defects in 
proliferation when cultured in a mix of growth factors that include Flt3L, but show minimal changes 
without Flt3L47. Another group has reported similar induction in the human AML cell line THP-1, which 
expressed wild-type FLT3, although no data was shown48. However, the role of Stat5 signaling on ligand-
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induced FLT3 signaling remains controversial, as several groups using similar and different cell lines 
have shown that Stat5/STAT5 phosphorylation is unique to mutated forms of FLT3 that lead to 
constitutive activation49-54. 
 
Flt3 expression in the hematopoietic system 
While Flt3L is expressed in an array of hematopoietic and non-hematopoietic cells, Flt3 
expression is more restricted and therefore becomes the limiting factor for signaling. The receptor is 
mainly restricted to the hematopoietic system in both mice and human, though RNA has also been 
detected in placenta, gonads, and neural tissue in mice55-57. While Flt3 was originally identified in a 
compartment enriched in HSCs, murine Flt3 expression within the hematopoietic system seems to 
correlate more with the loss of self-renewal58. Accordingly, Flt3 receptor is highly expressed in a number 
of early hematopoietic progenitors and does not seem to be expressed on HSCs, although more recent 
findings suggest that it may be expressed intracellularly in HSCs59. This is in contrast to humans, where 
surface FLT3 is expressed in both early progenitors and the CD34+ HSC compartment, and expression of 
the receptor correlates with multi-lineage engraftment in xenograft models60,61. Flt3 is mainly expressed 
on the surface of progenitors that are not fated to the megakaryocyte-erythroid lineage, which includes 
lymphoid-primed multipotent progenitors, common lymphoid progenitors (CLPs), proB cells, early thymic 
T cell progenitors, common myeloid progenitors, and a small subset of early granulocyte-monocyte 
progenitors (pre-GMPs)62-64. In line with this, mice deficient in Flt3L show reductions in CLPs, B cell 
precursors, NK cells, slight reductions in bulk myeloid progenitors, and reductions in pre-
GMPs/GMPs38,64,65, while mice deficient in Flt3 show reductions in the pro-B cell compartment66. 
Upon entry into circulation from the bone marrow, almost all hematopoietic cells lose the 
expression of Flt367. The main exceptions are DCs and their precursors pre-DCs, making DCs the only 
mature hematopoietic cell to actively express the receptor62. More importantly, signaling through Flt3 
plays a functional and significant role all throughout DC development and DC homeostasis67. Mice 
deficient in Flt3 show impairment in DC development, although those lacking Flt3L show more 
pronounced deficiencies38,68. Accordingly, in vivo administration of Flt3L increases DC numbers in both 
 13 
mice and human, while in vitro, it is sufficient to drive DC development from whole bone marrow 
cultures69,70. 
 
Tolerogenic role of Flt3 signaling 
Given the pivotal role of DCs in generating T cell responses, many researchers have used Flt3L 
as an adjuvant to increase DC production thereby improving protective T cell responses. This has been 
effective in overcoming models of peripheral tolerance, mounting tumor immunity, and protection against 
pathogens71-73. In this context, Flt3 signaling can be considered highly immunogenic, and is usually 
associated with DCs that have been activated and matured. However, in the steady state, DCs remain in 
a relatively immature state but still present self-antigen to induce tolerance by way of T cell deletion, T cell 
anergy, or regulatory T cells (Tregs). These Tregs are T cells that suppress the effector activity of 
conventional CD4+ and CD8+ T cells74-78. In fact, Flt3 signaling increases the levels of Tregs in the 
periphery and overall can generate a tolerogenic environment in different non-steady state conditions, 
including chronic ileitis, T cell mediated colitis, atherosclerosis, autoimmune diabetes, and graft-versus-
host disease79-83. In this context, Flt3 signaling can be considered tolerogenic. 
The simultaneous increase in both DCs and Tregs upon Flt3L administration suggests that there is 
regulatory link between the two populations mediated by Flt3 signaling. Indeed, Flt3L administration leads 
to increased numbers of both DCs and Tregs, while Flt3L deficiency leads to decreased numbers of both80. 
The increase in Tregs has mainly been attributed to the simple increase in DC numbers, but Flt3L-induced 
DC expansion activates specific signaling pathways and skews DC subsets, which may also affect Treg 
regulation45. Conversely, depletion of Tregs leads to an expansion of DCs, revealing a feedback control 
mechanism by Tregs to control DC numbers84. This DC expansion is dependent on Flt3, which further 
supports the crucial role of Flt3 in the DC-Treg feedback loop.  
 
Flt3 in acute myeloid leukemia 
Soon after mouse models showed the in vivo role of Flt3 in hematopoiesis, mutations within FLT3 
were identified in patients with acute myeloid leukemia (AML), a disease that results from aberrant clonal 
expansion of immature white blood cells that fills the bone marrow and ultimately leads to hematopoietic 
 14 
failure85. Discovery of these mutations in the context of human disease solidified the important role of Flt3 
signaling in hematopoiesis. Since then, it has been reported that approximately 30% of all AML patients 
harbor some form of FLT3 mutation, making it one of the most common genetic lesions encountered in 
AML86. Unfortunately, the clinical significance of these mutations is unfavorable for the patient. In addition 
to typically presenting with a large disease burden, the prognosis for patients harboring the mutation is 
mostly adverse86. While exact results vary between study groups, patients harboring FLT3 mutations 
generally show lower remission rates, increased relapse rates, and decreased overall survival compared 
to those that do not harbor the mutations87-89. 
Most patients succumb to the disease because there are very limited treatments available for 
AML. The current standard care of combination chemotherapy (cytarabine and anthracycline) was 
developed nearly 40 years ago and stem cell transplant, with all of its risks, is the only curable option90. 
Therefore, the field is in dire need of new forms of treatment. Given the prominence of FLT3 mutations, 
FLT3 seems like a prime candidate for molecular targeting. Unfortunately, early FLT3 tyrosine kinase 
inhibitors (TKIs) such as lestaurtinib and midostaurin, while promising in pre-clinical testing, failed to 
provide substantial and sustained responses in early clinical trials91. Consequently, this led many to 
question whether or not FLT3 mutations were simply passenger mutations. However, new and more-
specific FLT3 TKIs like quizartinib have shown good promise in early clinical trials, and there is now 
evidence that the leukemia confers a selective pressure to maintain FLT3 mutations in relapsed AML91,92. 
Together, these results affirm that FLT3 mutations are indeed driver mutations and that FLT3 TKIs may 
be promising treatments for AML. 
The most prevalent mutation among FLT3 AML mutations is the FLT3 internal tandem duplication 
(FLT3-ITD). The mutation is always found in-frame and can range from 3 to 400 base pairs long93. A 
majority of the FLT3-ITD mutations occur in the juxtamembrane domain, while about 30% of the 
mutations occur in the tyrosine kinase domain94.  Point mutations that lead to single amino acid changes 
within the activation loop of the tyrosine kinase domain also occur, but these are less common86. 
Nonetheless, activating FLT3 mutations lead to ligand-independent dimerization, autophosphorylation of 
the cytoplasmic domain, and subsequent activation of the pathway. It is believed that the elongation of 
the juxtamembrane domain found in FLT3-ITD mutations results in conformational changes that 
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aberrantly release inhibition of the kinase domain, as well as promotes dimerization31,51. These 
conformational changes have also been proposed to expose key residues in the juxtamembrane domain 
that serve as aberrant docking sites for STAT553. Mice that harbor the mutation acquire a monocytic 
myeloproliferative neoplasm which may be fatal, depending on mouse model, but rarely develop AML 
without cooperating mutations95-99. 
 
Cancer immunosurveillance and the role of DCs in the tumor microenvironment 
 The concept of cancer immunosurveillance, a process in which the immune system can detect 
and eliminate transformed cells before malignancy, was originally proposed 50-100 years ago100. Despite 
this, only recently has the immune system been appreciated as a significant contributor to cancer 
development in not only preventing tumorigenesis but also sculpting it in a way that inadvertently 
enhances tumor growth, also known as cancer immunoediting101,102. Several cell types and mechanisms 
from both the innate and adaptive immune systems have been proposed to contribute. From the innate 
immune system, CD8+ cDCs have been shown to contribute to the rejection of immunogenic sarcomas 
through their secretion of type I interferon103, and depletion of NK cells by antibody treatment has been 
shown to enhance tumor susceptibility to carcinogen-induced tumors104. From the adaptive immune 
system, Rag1- or Rag2-deficient mice, which lack T cells, B cells and natural killer T cells, also have 
enhanced susceptibility to carcinogen-induced tumors105. Rag2-deficient mice that additionally lack 
lymphocytes of the innate immune system show even higher tumor incidence106. Furthermore, the 
importance of the cytotoxic molecule perforin, which is expressed by cytotoxic lymphocytes like T cells 
and NK cells, has been demonstrated, as perforin-deficient mice display increased incidence of 
spontaneous lymphomas107. 
Several mechanisms involving DCs specifically have been proposed in solid tumors that 
ultimately promote an immunosuppressive environment. Many tumors subvert immunosurveillance by 
impairing the activity of immunogenic antigen-presenting DCs. For example, production of VEGF by a 
number of human cell lines has been shown to inhibit DC maturation from human HSCs, while other 
tumors have been shown to secrete factors that limit their migration to lymphoid organs108,109. In other 
cases, DCs have been shown to have an active role in generating an immunosuppressive environment. 
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In ovarian cancer, for instance, cDCs that express inhibitory receptor PD-1 and its ligand PD-L1 
accumulate in the tumor model and is associated with suppression of T cell activity, and pDCs have been 
proposed to promote immunosuppression by the recruitment of Tregs in human samples110,111. 
Impairment of immunosurveillance mechanisms involving DCs has also been proposed in 
AML112.  AML-derived DCs have been shown to be present in abnormal quantities and show functional 
impairment in their allostimulation of CD4+ T cells and cytokine secretion113. In addition, these DCs have 
also been proposed to induce T cell anergy in vitro114. Similar to solid tumors, AML-derived DCs have 
been shown to upregulate PD-L1 compared to healthy donors115. However, the general mechanisms of 
immune evasion in AML is relatively understudied compared to the many reports on solid tumors like 
melanoma116. Thus, our understanding of how DCs specifically contribute to the failure of 
immunosurveillance during AML is severely lacking. 
 
Given the unfavorable prognosis of FLT3-ITD+ AML patients compared to FLT3-ITD- AML 
patients, we considered additional leukemogenic mechanisms that may confer an advantage over other 
non-FLT3-mutated leukemias beyond cell-intrinsic transformation. Since Flt3 plays a key role in the 
immune system, especially during DC development, we hypothesized that constitutively active Flt3 
signaling may affect immunosurveillance mechanisms in a way that is conducive for leukemic survival. To 
this end, we explored the effect of the Flt3-ITD mutation in DCs and T cells and have unveiled early 




Flt3-ITD expands fully differentiated DCs and early DC progenitors 
To analyze the role of Flt3-ITD in the DC compartment, we utilized a mouse model in which a 
human internal tandem duplication sequence was knocked into the endogenous Flt3 murine locus95. Flow 
cytometric analysis of the DC compartment in multiple lymphoid organs in young adult mice showed 
significant expansion of both cDCs and pDCs (Figure 1.1) in heterozygous Flt3ITD/+ tissues, in both 
primary and peripheral lymphoid tissues, except in the thymus. This is in stark contrast to other 
hematopoietic lineages where more subtle changes occurred in the periphery. In particular, the only 
significant change seen in the periphery was a slight reduction in mature B cells (Figure 1.2B). In the 
bone marrow, these changes were more apparent in both the B cell compartment and monocyte 
compartment, which showed an increase in numbers (Figure 1.2A). Despite this, the DC compartment 
collectively was noticeably more affected than other mature hematopoietic lineages, as DCs showed the 
greatest fold change in frequencies in both bone marrow (BM) and spleen (Figure 1.3). cDCs showed up 
to a 4-fold increase compared to wild-type (WT), whereas monocytes at most showed a little less than a 
2-fold increase. Analysis of nonlymphoid tissues such as the small intestine showed a similarly robust 
expansion of cDC populations (Figure 1.4). 
When we analyzed the DC compartment in homozygous Flt3ITD/ITD mice, all tissues showed an 
even greater increase in these DC populations (Figure 1.1). However, unlike heterozygous Flt3ITD/+ mice, 
other hematopoietic lineages were severely affected. Specifically, mice showed a dramatic increase in the 
monocyte compartment and compromised B cell production in the BM and the periphery (Figure 1.2), 
which is in agreement with what has been described previously95. 
Cx3cr1GFP reporter mice have been useful tools to detect early DC progenitors, as MDPs, CDPs, 
and pre-DCs all express CX3CR113,117. To look at DC progenitors more precisely, we generated 
Cx3cr1GFP/+ Flt3ITD/+ and analyzed BM and spleen by flow cytometry using the gating strategy shown in 
Figure 1.5A-B. While MDPs did not show a significant increase, both CDPs and pre-DCs in the BM and 
spleen showed an expansion in absolute numbers (Figure 1.5C). Other lineage negative progenitors, 
including c-Kithi Flt3- (P1) and c-Kithi/lo Flt3+ CX3CR1+ CD115- (P2) were unaffected (Figure 1.5D). 
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Progenitors that were c-Kithi/lo Flt3+ CX3CR1- CD115- (P3) showed a decrease in numbers, which most 
likely consist of common lymphoid progenitors (Figure 1.5D). 
Together, these data show that Flt3-ITD preferentially expands both mature and early DC 
populations, while having more moderate effects on other mature hematopoietic cells. 
 
Expansion of DC populations is cell-intrinsic 
To test whether this DC expansion was cell-intrinsic, we generated competitive bone marrow 
chimeras and tracked donor contribution with the CD45 congenic marker, which marks all leukocytes. WT 
competitive (CD45.1+) and either Flt3+/+, Flt3ITD/+, or Flt3ITD/ITD donor (CD45.2+) bone marrow were injected 
into lethally irradiated F1 B6x129 recipients (CD45.1+/CD45.2+) at a 1:1 ratio. 14 weeks post transfer, BM, 
spleen, skin-draining lymph nodes, and thymi were analyzed (Figure 1.6, data not shown). Data were 
analyzed by quantifying cell type contribution out of respective total donor population within each tissue, 
as represented in Figure 1.6A. In all tissues, expansion of cDCs occurred only in donor Flt3ITD/+ and 
Flt3ITD/ITD CD45.2+ cells (Figure 1.6A-B). pDCs showed a similar expansion in heterozygous donor Flt3ITD/+ 
cells, but this expansion was not consistent among tissues in chimeras harboring Flt3ITD/ITD cells (Figure 
1.6C), likely due to the proportional expansion of other lineages. Analysis of early DC progenitors in the 
bone marrow also exhibited expanded populations only in Flt3ITD/+ expressing bone marrow (Figure 1.7A). 
As DC progenitors are identified by their expression of Flt3, DC progenitors in homozygotes were difficult 
to identify due to downregulation of the surface Flt3 receptor (Figure 1.7B; 1.8C-D). However, alternative 
gating without the use of Flt3 suggests that CDPs are expanded in a cell-extrinsic manner as well (Figure 
1.7B-C). These data indicate that the expansion of DC populations by Flt3ITD/+ mutation is cell-intrinsic. 
 
Flt3-ITD causes downregulation of surface Flt3 receptor on DCs and abrogates exogenous Flt3 signaling 
Downregulation of the Flt3 receptor in Flt3ITD BM have been described before118,119, however Flt3 
expression specifically on DCs has not been explored. Therefore we analyzed Flt3 cell surface 
expression by flow cytometry in peripheral DCs and CDPs in the BM. Analysis of surface Flt3 expression 
in competitive chimeras (described above) showed that Flt3 expression is significantly downregulated in 
Flt3ITD/ITD-expressing cDCs, pDCs, and CDPs, but not in the WT competitor (Figure 1.8). Moderate cell-
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extrinsic downregulation of Flt3 in WT CDPs was also seen (Figure 1.8D). Interestingly, heterozygous 
Flt3ITD/+ cells showed differential Flt3 downregulation among DC populations. Specifically, no 
downregulation was seen in heterozygous cDCs, while partial downregulation was seen in heterozygous 
pDCs and CDPs (Figure 1.8B,D). 
In order to test how this downregulation of Flt3 expression affects Flt3L-induced DC development, 
we cultured whole bone marrow cells from Flt3+/+, Flt3ITD/+ and Flt3ITD/ITD mice with murine Flt3L in variable 
concentrations and measured DC output. Without exogenous Flt3L, neither Flt3ITD/+ nor Flt3ITD/ITD was 
sufficient to drive DC development in vitro (Figure 1.9A). In the presence of Flt3L, only Flt3+/+ and Flt3ITD/+, 
but not Flt3ITD/ITD, generated robust populations of both cDCs and pDCs. Notably, Flt3ITD/+ cultures 
generated pDCs in a dose dependent manner. These data suggest that Flt3-ITD downregulates Flt3 
surface expression on DCs and renders them insensitive to exogenous Flt3L signaling. 
 
Flt3-ITD skews cDC subsets 
In vitro Flt3L cultures of Flt3ITD/+ indicated that there was developmental bias towards generating 
more CD8+-like cDCs (Figure 1.9B-C). While this bias was not apparent in vivo, we decided to perform 
whole genome expression analysis on ex vivo splenic Flt3ITD/+ CD8+ cDCs to investigate whether or not 
Flt3ITD/+ affected the genetic repertoire of the DCs. Consistent with what was seen in vitro, whole genome 
analysis indicated that CD8+ cDCs were most affected by the ITD mutation, as more genes showed 
differential expression compared to those found in CD11b+ cDCs or pDCs (Figure 1.10). Interestingly, 
Flt3ITD/+ CD8+ cDCs showed a genetic signature that was very similar to that of non-canonical CD8+ cDCs, 
as many of the genes upregulated in non-canonical CD8+ cDCs were upregulated in Flt3ITD/+ CD8+ cDCs20 
(data not shown). To this end, we analyzed the effect of Flt3-ITD on specific subgroups using the 
Cx3cr1GFP/+ reporter mice, which readily distinguishes CD11b+ and CD8+ cDC subsets by GFP expression 
as shown in Figure 1.11A. While all subgroups were increased in Flt3ITD/+ spleens (Figure 1.11B), there 
was a greater representation of CX3CR1+ subgroups within both CD8+ and CD11b+ cDCs, especially 
within the CD8+ cDC compartment (Figure 1.11A,C). In contrast, Flt3L administration to Cx3cr1GFP/GFP 
mice showed a significant bias towards GFP- canonical CD8+ cDCs (Figure 1.11D,E), suggesting that the 
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population of cDCs generated by constitutive Flt3 signaling from Flt3ITD/+ expression was not the same as 
those yielded by Flt3L-induced signaling. 
Microarray analysis also indicated that inhibitory ligand PD-L1 was one of several cell-surface 
markers that was upregulated in Flt3ITD/+ CD8+ cDCs (data not shown). Consequently, we analyzed the 
cell surface expression of PD-L1 on our Flt3ITD/+ mice and noticed that there was a greater proportion of 
PD-L1+ CD86- CD8+ cDCs (Figure 1.12A). Analysis of these same sub-populations in Cx3cr1GFP reporter 
mice showed that these PD-L1+ CD8+ cDCs uniformly expressed GFP (Figure 1.12B), indicating that our 
PD-L1+ CD8+ cDC subset represented these non-canonical CD8+ cDCs. 
Non-canonical CD8+ cDC have been reported to be developmentally independent of transcription 
Batf320. Consistent with this, Batf3-/- mice show a specific depletion of canonical CD86+ PD-L1- CD8+ 
cDC, leaving only residual non-canonical PD-L1+ CD8+ cDCs behind (Figure 1.13A). Furthermore, Batf3-/- 
Flt3ITD/+ mice show a selective expansion of the non-canonical PD-L1+ CD8+ cDCs (Figure 1.13A), which 
were also negative for DEC205 (Figure 1.13B). Of note, in older mice we see a variable accumulation of 
CD86+ PD-L1+ population in Batf3-/- Flt3ITD/+ mice (data not shown). Further characterization of this 
population is still under investigation. 
To test the functional consequence of this CD8+ subset expansion, we infected mice with Listeria 
monocytogenes, which has been shown to use canonical CD8+ cDCs as an entry-point for bacterial 
spreading120. Flt3ITD/+ mice showed increased bacterial load, as expected given the expansion of 
canonical CD8+ cDCs (Figure 1.14). Meanwhile, Batf3-/- Flt3ITD/+ mice were resistant to Listeria infection, 
similar to Batf3-/- Flt3+/+ mice, despite the increase in absolute cell numbers in CD8+ cDCs, suggesting 
that non-canonical CD8+ cDCs cannot compensate for the canonical CD8+ cDC capabilities.  This data 
provides a functional correlate for the specific pattern of DC subset expansion by Flt3-ITD.  
 
Flt3-ITD expands T cells in a cell-extrinsic manner 
Flow cytometric analysis of T cell numbers in the steady state of naïve mice showed virtually no 
change in conventional T cell (Tconv) numbers (Figure 1.15A) but showed a dose-dependent expansion of 
regulatory T cells (Tregs) in BM (Figure 1.15B). Analysis of T cell populations in mixed chimeras showed 
an expansion of both Tconv cells and Tregs strictly in the WT competitor and host T cells, but not in the 
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Flt3ITD-expressing T cells (Figure 1.16A,B; data not shown). Interestingly, this cell-extrinsic expansion was 
mainly found in chimeras reconstituted with heterozygous Flt3ITD/+ cells, and was most affected within the 
chimeric bone marrow. 
To test how Flt3ITD/+ DCs affect antigenic stimulation of T cells, we set up allogeneic mixed 
leukocyte reactions by incubating various doses of CD11c+ enriched splenocytes with magnetically sorted 
bulk T cells from FoxP3GFP/+ reporter mice, which allowed us to identify Tregs using GFP expression. At all 
doses, Flt3ITD/+ DCs induced a greater number of CD4+ Tconv cells, CD8+ Tconv cells, and Tregs (Figure 
1.17A). In addition, all T cell populations showed a greater proportion of proliferated cells, as measured 
by Cell Trace Violet dye (Figure 1.17C). These results suggest that expression of Flt3-ITD on DCs 
generally enhances antigen-driven T cell proliferation. 
We also tested the effect of Flt3-ITD on lymphopenia-induced proliferation of T cells by adoptive 
transfer of bulk T cells into Rag1-deficient mice, which lack B or T cells. Presence of the Flt3-ITD resulted 
in higher numbers of both Tconv cells and Tregs (Figure 1.18A) that had either remained or undergone 
homeostatic proliferation as measured by Cell Trace Violet dye (T cells that had completely diluted out 
the dye and therefore represent microbiota-induced spontaneous proliferation were excluded). 
Interestingly, there was no significant difference in the proportion of proliferative Tconv cells (Figure 1.18B) 
despite the increased number of cells. Additionally, no significant difference was seen in cells that 
underwent spontaneous proliferation (data not shown). These data suggest that Flt3-ITD also enhances 
the survival of T cells reconstituted in a lymphopenic environment. 
 
Flt3-ITD increases Treg proportions in the T cell compartment and dampens aGVHD response 
Closer analysis of competitive chimeras showed that while all Tconv cells and Tregs increased in a 
cell-extrinsic manner, these populations did not increase equally. Specifically, mice harboring Flt3ITD/+ 
bone marrow led to an increased percentage of WT Tregs out of total WT competitor T cells (Figure 
1.16C). Similarly, the mixed leukocyte reactions incubated with the Flt3ITD/+ CD11c-enriched population 
resulted in a greater proportion of Tregs out of total responder T cells (Figure 1.17B). To analyze how 
Flt3ITD/+ affects Treg homeostasis specifically, we crossed Flt3ITD/+ mice with FoxP3DTR-GFP, which allows 
both detection as well as specific depletion of Tregs by administration of diptheria toxin (DT)84. Before 
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depletion, we did see a greater proportion of Tregs in spleen and peripheral blood in the steady state in 
these reporter mice (Figure 1.19A,C), likely due to the more sensitive readout by GFP. After DT 
administration, Flt3ITD/+ facilitated a more robust reconstitution of peripheral blood Tregs than in Flt3+/+ at all 
time points tested (Figure 1.19A), and maintained a greater proportion of Tregs in the spleen and thymus 
even after Treg depletion (Figure 1.19B). Thus, Flt3ITD/+ facilitates the presence of more Tregs in the 
periphery. 
Flt3L treatment has been shown to ameliorate the acute graft-versus-host (aGVH) response in 
mice83. Therefore, we tested whether Flt3-ITD may have similar tolerogenic effects by setting up a parent 
to-F1 transplant as a model for aGVH-mediated self-reactivity. Cells from spleen and lymph nodes of WT 
B6 (CD45.2+) were injected into non-irradiated B6xFVB F1 hosts (CD45.1+/CD45.2+) that were Flt3+/+ or 
Flt3ITD/+, and graft response was measured by expansion of graft T cells (CD45.1-) one week after 
transplant. Hosts harboring the Flt3-ITD allele displayed a reduced frequency and number of graft T cells 
compared to the control (Figure 1.20A,B), indicating that Flt3-ITD hosts were able to reduce the burden of 
self-reactive T cells in vivo. Meanwhile, host T cells exhibited an increased proportion of host Tregs (Figure 
1.20C). Given the expansion of PD-L1 expressing cDCs (Figure 1.12A), we tested whether this 
dampening of aGVH response was dependent on PD-L1 or the PD-1 pathway by treating recipients with 
"-PD-L1 and "-PD-1 blocking antibodies. As seen in Figure 1.21, while the blockage of PD-1 enhanced 
the aGVHD response (1.21B), the dampening effect of Flt3ITD/+ on graft T cell expansion still remained 
(1.21A,B), indicating that this tolerogenic effect is not dependent on the PD-L1/PD-1 pathway. 
Finally, to test whether this dampening effect of self-reactive T cells was dependent on Tregs, we 
crossed Flt3ITD/+ mice with FoxP3sf (scurfy) mice that lack functional Tregs and develop lethal T cell-
mediated autoimmunity. If Flt3-ITD directly impaired self-reactive effector T cell responses, one would 
expect that the autoimmunity in Flt3ITD/+ FoxP3sf mice would be ameliorated. Contrary to this notion, we 
found that these mice succumbed to the disease significantly sooner than Flt3+/+ FoxP3sf littermates 
(Figure 1.22). Collectively, these results suggest that Flt3-ITD mutation causes a preferential expansion 





Connecting the roles of Flt3 signaling in leukemogenesis and the immune system 
Activating FLT3 mutations are one of the most common genetic lesions found in AML and is 
highly associated with poor prognoses. Hence, much attention has been focused on studying the role of 
Flt3 within the context of leukemogenesis. Given its prominent expression of Flt3 in undifferentiated early 
progenitors and its role in cell survival and proliferation, most of the leukemia-promoting characteristics 
have been attributed to aberrant activation and function within these early progenitors. However, the DC 
lineage is the only portion of normal hematopoiesis that expresses the Flt3 receptor and utilizes its 
signaling continuously throughout maturation, unlike most other lineages that lose expression upon 
differentiation. Moreover, Flt3L signaling has profound tolerogenic consequences mediated through the 
activity of Tregs. Thus, Flt3 also has a prominent role within the immune system as a crucial regulator of 
DC development and Treg homeostasis. To this end, we explored the role of Flt3-ITD within the immune 
system, specifically on DC development and the effect on T cell responses. Here we provide evidence of 
the immunological consequences of activated Flt3-ITD signaling beyond the more established cell-
intrinsic mechanisms of leukemic transformation within the early progenitor compartment. 
 
Flt3-ITD preferentially expands DCs 
Consistent with the effects of Flt3L signaling, the most striking phenotype that we observed was 
in DCs. One allele of Flt3-ITD was sufficient to drive DC development and promote expansion of all DC 
cell types even at the progenitor level, while having very moderate effects on other fully mature 
hematopoietic cells. This was unlikely due to increased Flt3L in the serum, as earlier reports have shown 
that Flt3L levels do not change significantly in Flt3ITD/+ mice96,121. In agreement with this, we showed 
through competitive chimeras that this expansion was strictly cell-intrinsic and was even more 
pronounced in the homozygote. This is in contrast to what has been described by another group, in which 
heterozygote Flt3ITD/+ mice exhibit severe alterations in other myeloid populations and progenitors, and 
the mice succumb to a fatal myeloproliferative disease96. Of note, this group utilizes a different mouse 
strain from the one used in this study. Additionally, previous data corroborates with our data, in that 
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hematopoiesis is largely normal in the heterozygote Flt3ITD/+ mouse strain that we use95,121. Overall, 
similarly to normal Flt3L signaling, Flt3-ITD heavily promotes dendritic cell development. 
 
Flt3-ITD downregulates the surface receptor and impairs Flt3L-induced signaling 
As seen in myeloid progenitors121, Flt3-ITD also caused the downregulation of Flt3 receptor 
expression and desensitized DCs to exogenous Flt3L signaling, suggesting that Flt3-ITD activity acts 
independently of exogenous Flt3L. As seen in our in vitro cultures, Flt3-ITD signaling does not entirely 
recapitulate Flt3L signaling, as Flt3-ITD signaling alone was not sufficient to drive DC development, but is 
more than proficient at driving it in vivo. This may reflect the difference in signaling between the two, in 
which Flt3-ITD lacks some of the signaling components required to drive development in vitro. In vivo, 
other cytokine signaling may be present to support or synergize with Flt3-ITD-mediated DC expansion, 
while in vitro no such support exists. Furthermore, this downregulation of surface Flt3 receptor certainly 
may have implications on immunotherapy. For example, antibody-mediated anti-Flt3 therapies for AML 
may be less effective, as cell surface availability would very much limit binding to the receptor. 
 
Flt3-ITD preferentially expands a non-canonical cDC subset 
Inconsistent with the effects of Flt3L signaling, Flt3-ITD preferentially expanded the non-canonical 
subset of CD8+ cDCs. In our hands (Figure 1.11E) as well as in the hands of others20, Flt3L treatment has 
been shown to significantly promote the expansion of canonical CD8+ cDCs. Surprisingly, this was not the 
case for Flt3-ITD-expanded cDCs, as there was a greater representation of the non-canonical subtype. 
These cells appear CD8+-like and genetically pDC-like, but lack the many functional hallmarks that are 
unique to these cell types, like IL-12 production, cross-presentation, and interferon production20. Since 
non-canonical CD8+ cDCs do not significantly respond to Flt3L, it is possible that Flt3-ITD may aberrantly 
activate proliferative pathways within these cells that are normally not activated with Flt3L signaling 
specifically. Stat5, for example, has been shown to be aberrantly activated in cell lines expressing Flt3-
ITD, and may play a role in promoting the expansion of this normally minor cDC subset. More importantly, 
we have shown by Listeria infection that these non-canonical CD8+ cDCs cannot substitute for their 
canonical counterparts, even when increased in cell numbers. This subset skewing may have important 
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implications on tumor immunity, as canonical cross-presenting CD8+ cDCs have been critical in T cell-
mediated cytotoxicity of tumor cells17. The increasing proportion of a non-cross-presenting CD8+ cDC may 
influence the ability for the immune system to reject the leukemia. Interestingly, recent studies have 
described a cDC/pDC “precursor” cell that expressed both cDC and pDC human markers and is found in 
low numbers in healthy patient samples122.  This study demonstrated that there was a higher 
accumulation of these mixed-lineage cells in FLT3-ITD+ patient samples than in FLT3-ITD- AML samples. 
While these cells are reminiscent of the cDC/pDC-like attributes of murine non-canonical CD8+ cDCs, 
further investigation is required to see if human counterparts exist, especially in AML patients. 
 
Flt3-ITD promotes Treg homeostasis and can attenuate self-reactivity 
While we have shown the Flt3-ITD cell-extrinsically expands both conventional T cells and Tregs, 
the relative proportions of Treg to Tconv cells may ultimately matter. We have shown that Flt3-ITD does 
indeed favor the expansion of Tregs and their overall proportion among the T cell compartment in the 
steady state, antigen-induced T cell proliferation, and within the host compartment in aGVH response. 
This increased proportion was associated with an attenuated aGVH response, thus recapitulating the 
tolerogenic responses seen with Flt3L83. We provide further support that the attenuation of self-reactivity 
is dependent on Tregs, as Flt3-ITD was unable to ameliorate the fatal autoimmunity exhibited in Treg-
deficient scurfy mice.  
 
Flt3-ITD - an immunomodulating mutation that promotes leukemogenesis 
Together, these results cultivate the notion that Flt3-ITD may establish a tolerogenic environment 
through DC expansion and subsequent expansion of Tregs, and that this may play a role in disabling 
immunosurveillance mechanisms in leukemogenesis. The expansion of DCs coinciding with the 
expansion of Tregs is reminiscent of normal Flt3L signaling which has been associated with many 
tolerogenic conditions. The additional effects on the immune system may therefore explain the 
prevalence of FLT3-ITD+ AML and its association with a higher incidence of relapse. Flt3-ITD has already 
been shown to have effects on normal hematopoiesis that would enhance its ability to promote 
leukemogenesis at the cell-intrinsic progenitor level. These include the impairment of HSC quiescence 
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and promotion of a myeloid-based transcriptional program at the expense of lymphopoiesis59,119. In this 
study, we propose another component downstream of the leukemic stem cell clone that is unique to Flt3-
ITD – the induction of tolerance mediated by DCs and Tregs (Figure 1.23). For this to occur, HSCs 
harboring the FLT3-ITD mutation would give rise to FLT3-ITD DCs early in leukemogenesis, before the 
clinical manifestations of AML, as only one hit of ITD is required to affect the immune system in our 
murine model. DCs would likely acquire the mutation quickly, since DCs have a short half-life and are 
frequently replenished by progenitors10,123. The expansion of DCs conferred by the FLT3-ITD mutation 
would then lead to a favored expansion of Tregs that would establish an immunosuppressive environment 
that is permissive for leukemic growth. In agreement, the FLT3-ITD mutation has been identified in pre-
leukemic and leukemic HSCs124,125, and found in DCs harvested from FLT3-ITD+ AML patients, which 
interestingly also show impaired cytokine secretion and an accumulation122,126. Furthermore, increased 
Treg frequencies have been reported in AML patients127. Moreover, the tolerogenic effect of FLT3-ITD on 
the immune system would not only promote de novo AML, but may also promote the failure of graft-
versus-leukemia response from allogeneic transplant, thus providing an explanation for the increased risk 
of relapse.  Accordingly, it has been demonstrated that AML patients that harbor the FLT3-ITD mutation 
have higher incidence of relapse than FLT3-ITD-negative patients after receiving allogeneic transplant128. 
 
Overall, our studies reveal a novel immunological effect of Flt3-ITD during normal hematopoiesis 
that results in the expansion of DCs and the subsequent alteration of T cell homeostasis and function. 
This previously unappreciated feature would prompt investigations on immunosurveillance in AML 
development and potential complementary immunotherapy strategies to fight the disease. 
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MATERIALS AND METHODS 
 
Animals 
All mice were on C57BL/6 background, unless otherwise indicated. Flt3ITD/+ mice95, Cx3cr1GFP/GFP mice117,  
Batf3-/- mice17, Rag1-/- mice129, FoxP3DTR-GFP mice84, and FoxP3Sf mice were purchased from Jackson 
Laboratories, while WT FVB/N mice were purchased from Taconic. FoxP3GFP mice130 were a kind gift from 
Dr. Kang Liu. Recipients for competitive chimeras were F1 progeny of 129SvEv (Taconic) and B6.SJL 
(Taconic). For Treg depletion model, homozygous FoxP3DTR-GFP/DTR-GFP females were crossed to 
heterozygous Flt3ITD/+ males, and only male progeny were used for the study. For aGVH model, FVB/N 
females were crossed to Flt3ITD/+ males to generate F1 recipients. For T cell-mediated autoimmunity 
model, heterozygous FoxP3sf/+ females were bred to heterozygous Flt3ITD/+ males, and only male progeny 
that exhibited disease phenotypes (runting, scaly skin on ears and tails, and hunched posture) were 
included in the study. All animal studies were performed according to the investigator’s protocol approved 
by the Institutional Animal Care and Use Committee of Columbia University. 
 
Cell preparations 
Spleen, thymus, and lymph nodes (inguinal, axillary, brachial, and cervical) were minced and pressed 
through a nylon cell strainer to yield single cell suspensions and then subjected to red blood cell (RBC) 
lysis before being filtered. Bone marrow was prepared by flushing femurs and tibias with phosphate buffer 
saline (PBS) using a 27-gauge needle before RBC lysis. For dendritic cell (DC) analysis, lymphoid organs 
were digested with collagenase D (1 mg/mL) and DNaseI (20µg/mL) in DMEM/10% FCS for 30-60 min at 
37°C prior to generating cell suspensions and RBC lysis. Small intestine lamina propria lymphocytes were 
prepared as described before131. 
 
Flow cytometry 
Cells were stained with the following fluorochrome- or biotin-conjugated antibodies from eBioscience or 
as indicated: anti-CD11c (N418), MHC II (M5/114.15.2), CD11b (M1/70), CD8! (53-6.7), Gr-1 (RB6-8C5), 
TCR" (H57-597), CD3 (17A2), B220 (RA3-6B2), NK1.1 (PK136), Ter119 (TER-119), CD49b (DX5), CD4 
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(RM4-5 and GK1.5), FoxP3 (FJK-16s), CD24 (M1/69), Flt3 (A2F10), c-Kit (2B8), Sca-1 (D7), CD115 
(AFS98), IL7-R! (A7R34), CD45.1 (A20), CD45.2 (104), PD-L1 (MIH5), CD86 (GL1), DEC205 (NLDC-
145; BioLegend), mPDCA-1/Bst2 (Miltenyi Biotec), Sirp! (P84, BD Biosciences). Intracellular staining of 
FoxP3 was performed per manufacturer’s instructions (eBioscience). Cell acquisition was done on LSR II 
(BD Biosciences) using FACSDiva (BD Biosciences) and analysis was done on FlowJo (Tree Star). 
 
Competitive chimeras 
Bone marrow from B6-SJL (CD45.1+) and Flt3+/+, Flt3ITD/+, and Flt3ITD/ITD (CD45.2+) were prepared as 
described above. 129-B6.SJL F1 recipients (CD45.1+/CD45.2+) were lethally irradiated with two doses of 
600 cGy prior to receiving a mix of 1 x 106 B6.SJL bone marrow and 1 x 106 Flt3+/+, Flt3ITD/+, or Flt3ITD/ITD 
bone marrow cells intravenously in PBS/1% FCS. Peripheral blood was checked 4 weeks after transplant 
to confirm engraftment. Bone marrow, spleens, lymph nodes, and thymi were harvested and prepped for 
DC analysis as described above. 
 
In vitro BM-derived DC cultures 
Bone marrow cells were harvested as described above. RBC-lysed cells were plated in triplicates in a 24-
well plate at 2 x 106 per well in DMEM/10% FCS and various concentrations of recombinant murine Flt3 
ligand (PeproTech) as indicated. Suspension and adherent cells were harvested after 7 days and 
triplicates were pooled for counting and flow cytometric analysis. 
 
Flt3L administration 
Cx3cr1GFP/GFP mice were injected intraperitoneally with PBS or 5 µg recombinant Flt3L-Fc (LakePharma) 
every 3 days (d0, d3, d6) and analyzed on day 9 after initial treatment. Spleens were harvested for flow 
cytometry and prepared as described above for DC analysis. 
 
Listeria monocytogenes infection 
Mice were infected with 5 x 103 CFU of Listeria monocytogenes expressing OVA in PBS and injected 
intravenously. For bacterial titration, spleens were weighed and then pressed into nylon strainers to make 
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single cell suspensions in sterile PBS. Cells were lysed with equal volume of sterile water with 0.1% 
Triton X-100, and plated on brain heart infusion agar plates (Difco, BD Biosciences) for overnight 
incubation at 37°C. Colonies were counted the next day. 
 
Lymphopenia-induced homeostatic proliferation 
Spleen and lymph nodes were isolated from FoxP3GFP reporter mice and prepared as described above. T 
cells were negatively selected by MACS columns per manufacturer’s instructions (Miltenyi Biotec) using 
streptavidin microbeads and the following biotinylated antibodies: anti-CD11b, CD11c, B220, Gr-1, 
CD49b, and Ter119. T cells were stained with 5 µM Cell Trace Violet (Life Technologies) in PBS for 20 
minutes at 37°C and washed with RPMI/10% FCS. 2 x 106 bulk T cells resuspended in PBS/1% FCS 
were injected intravenously into Rag1-/- Flt3+/+ or Rag1-/- Flt3ITD/+ recipients. Spleens were harvested and 
analyzed 5 days after transfer by flow cytometry. 
 
Allogeneic mixed leukocyte reaction 
For stimulator isolation: Splenic DCs were prepared from C57BL/6-FVB/N F1 progeny by positive 
selection using biotinylated anti-CD11c, streptavidin microbeads, and MACS columns, per manufacturer’s 
instructions (Miltenyi Biotec). For responder T cell isolation: T cells from FoxP3GFP/GFP (C57BL/6) spleen 
and lymph nodes were negatively selected by MACS columns per manufacturer’s instructions (Miltenyi 
Biotec) using streptavidin microbeads and the following biotinylated antibodies: anti-CD11b, CD11c, 
B220, Gr-1, CD49b, and Ter119. T cells were stained with 5 µM Cell Trace Violet (Life Technologies) in 
PBS for 20 minutes at 37°C and washed with RPMI/10% FCS. 5 x 104 bulk T cells were plated on a 96-
well plate in RPMI/10% FCS with various amounts of CD11c-enriched stimulator cells, as indicated, and 
incubated for 4 days at 37°C and 5% CO2. 
 
Treg depletion 
FoxP3DTR-GFP/y Flt3+/+ and FoxP3DTR-GFP/y Flt3ITD/+ mice were injected intraperitoneally with diptheria toxin 
(Sigma) resuspended in PBS at 50 µg/kg each day for 2 days. Blood was retrieved and analyzed for 
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presence of GFP+ Tregs on day 0 (initial treatment), 2, 10, 14, 21, and 28, and mice that showed no 
depletion were excluded from analysis. End-point analysis of spleen and thymus occurred on day 28. 
 
Acute graft-versus-host model 
Spleen and lymph nodes were isolated from WT C57BL/6 (H-2b; CD45.2) mice and single cell 
suspensions were subject to red blood cell lysis and filtered. 30 x 106 cells of pooled cells were injected 
intravenously into nonirradiated C57BL/6-FVB/N F1 recipients (H-2b/H-2q; CD45.2/CD45.1). Spleens were 
harvested and analyzed 1 week later. For antibody blockade studies, 200 µg of control IgG, anti-mPD-L1 
(10F.9G2) or anti-mPD-1 (RMP1-14) were intraperitoneally injected same day prior to graft transfer on 




Statistical significance was estimated with unpaired, two-tailed Student’s T test. For survival curves, 
statistical significance was measured with log-rank (Mantel-Cox) test. 
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Figure 1.1. Expansion of mature DC populations in Flt3ITD mice. 
(A)  Representative staining prolifes for cDCs (left) and pDCs (right) in bone marrow (BM), spleen 
(SPL), lymph nodes (LN), and thymus (THY) of naïve Flt3+/+, Flt3ITD/+, or Flt3ITD/ITD mice. 
Numbers indicate frequency of DCs within the gated population. In LN, CD11chi MHCII+ cDCs 
represent resident cDCs, while CD11clo MHCIIhi represent migratory cDCs.  
(B)  Frequencies (top row) and absolute cell numbers (bottom row) of cDCs (mean ± SD, n = 5; 
9.5-12.5 wks old)  
(C)  Frequencies (top row) and absolute cell numbers (bottom row) of pDCs (mean ± SD, n = 5; 
9.5-12.5 wks old) 
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Figure 1.2. Flt3ITD/+  shows minimal effect on other mature myeloid populations, while Flt3ITD/ITD  
reveals myeloid skewing.  
(A-B)  Frequencies (top row) and absolute numbers (bottom row) of myeloid cells and B-cells in bone 
marrow (A) and spleen (B) of naïve Flt3+/+, Flt3ITD/+, or Flt3ITD/ITD mice. (mean ± SD, n = 5; 
9.5-12.5 wks old)  
 Lineages were defined as follows: granulocytes (Gr-1hi CD11b+ SSChi FSChi), monocytes 
(Gr-1int/- CD11b+ MHCII- FSClo SSClo), macrophages (Gr-1int/- CD11b+ MHCII- SSChi FSCint), 
immature B-cells (B220lo MHCIIlo Bst2-), mature B cells (B220hi MHCIIhi Bst2-).  





















































































































































































































































































































































Figure 1.3. Flt3-ITD shows a selective expansion in DC populations.  
Fold change between Flt3+/+ and Flt3ITD/+ cell types in BM and SPL of naïve mice. To calculate fold 
change, individual Flt3ITD/+ cell frequencies were normalized to the Flt3+/+ mean frequency for each 
tissue cell type. Dotted line delineates fold change of 1. (mean ± SD, n = 5; 9.5-12.5 wks old).  
Lineages were defined as follows: granulocytes (Gr-1hi CD11b+ SSChi FSChi), monocytes (Gr-1int/- 
CD11b+ MHCII- FSClo SSClo), macrophages (Gr-1int/- CD11b+ MHCII- SSChi FSCint), immature B-cells 

























































































Figure 1.4. Flt3-ITD expands DCs in non-lymphoid tissues.  
Flow cytometric analysis of lamina propria lymphocytes isolated from naïve Flt3+/+ or Flt3ITD/+ small 
intestine. Numbers indicate percent of cells within gated population. Representative of two 
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Figure 1.5. Flt3-ITD expands DC progenitors. 
(A)  Representative gating strategy for macrophage/DC progenitor (MDP), common DC progenitor 
(CDP), and non-DC progenitor populations in Cx3cr1GFP/+ bone marrow.  
(B)  Representative gating strategy for pre-DCs in Cx3cr1GFP/+ bone marrow. Similar gating 
strategy was used for spleen.  
(C)  Absolute numbers of MDPs, CDPs, and pre-DCs, as defined in (A) and (B) in bone marrow 
(BM) and spleen (SPL) (mean ± SD, n = 5; 6-9 wks old).  
(D)  Absolute numbers of non-DC progenitors as defined in (A) in bone marrow (mean ± SD, n = 5; 
6-9 wks old). 
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Figure 1.6. Flt3-ITD expands DCs in a cell-intrinsic manner.  
Lethally irradiated recipients (CD45.1+/CD45.2+) were reconstituted with a 1:1 ratio of CD45.1+ WT 
competitor and CD45.2+ Flt3+/+, Flt3ITD/+, or Flt3ITD/ITD donor bone marrow. Bone marrow (BM), spleen  
(SPL), and lymph nodes (LN) were analyzed 14 weeks after transfer by flow cytometry.  
(A)  Representative staining profiles of cDC contribution from total CD45.1+ WT competitor and 
CD45.2+ donor cells within SPL. Numbers on the plots show percent of cells within the gated 
population. 
(B)  Percent of cDCs out of total WT competitor CD45.1+ cells (white bars) or donor CD45.2+ cells 
(blue bars) as defined in (A) (mean ± SD, n = 4-5). 
(C)  Percent of pDCs out of total WT competitor CD45.1+ cells or donor CD45.2+ cells. pDCs were 
defined as B220+ CD11clo MHCIIlo/- CD11b- (mean ± SD, n = 4-5).   
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Figure 1.7. Flt3-ITD expands DC progenitors in a cell-intrinsic manner.  
Lethally irradiated recipients (CD45.1+/CD45.2+) were reconstituted with a 1:1 ratio of CD45.1+ WT 
competitor and CD45.2+ Flt3+/+, Flt3ITD/+, or Flt3ITD/ITD donor bone marrow. Bone marrow (BM) and 
spleen (SPL) were analyzed 14 weeks after transfer by flow cytometry.  
(A)  Percent of CDPs and pre-DCs out of total WT competitor CD45.1+ cells (white bars) or donor 
CD45.2+ cells (blue bars)(mean ± SD, n = 4-5). CDPs were defined as as Lin- (B220, CD3, 
NK1.1, CD11b, Gr-1, Ter119, CD11c) Sca-1- c-Kitlo Flt3+ CD115+; and pre-DCs as Lin- (B220, 
CD3, NK1.1, CD11b, Gr-1, Ter119) CD11c+ MHCII- Flt3+ Sirp!-.  
(B)  Representative staining profiles of the alternative gating for CDP. Left column of plots are pre-
gated on Lin- (B220, CD3, NK1.1, CD11b, Gr-1, Ter119, CD11c) Sca-1- IL7R-. Wild-type 
competitor cells were defined as CD45.1+, while CD45.2+ donor Flt3+/+, Flt3ITD/+, or Flt3ITD/ITD 
cells were defined as CD45.1-.  
(C)  Percent of alternatively-defined CDPs out of total WT competitor CD45.1+ cells or donor 
CD45.2+ (CD45.1-) cells as shown in (B)(mean ± SD, n = 4-5). 
Statistically significant differences are indicated as: * p < 0.05 ; ** p < 0.01 ; *** p < 0.001 
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Figure 1.8. Flt3-ITD causes downregulation of surface Flt3.  
Lethally irradiated recipients (CD45.1+/CD45.2+) were reconstituted with a 1:1 ratio of CD45.1+ WT 
competitor and CD45.2+ Flt3+/+, Flt3ITD/+, or Flt3ITD/ITD donor bone marrow. Bone marrow (BM) and 
spleen (SPL) were analyzed 14 weeks after transfer by flow cytometry.  
(A)  Representative histograms of Flt3 expression on splenic cDCs and pDCs on WT CD45.1+ 
competitor and CD45.2+ donor cells (Flt3+/+, Flt3ITD/+, or Flt3ITD/ITD). Dotted line shows mean 
fluorescent intensity (MFI) of Flt3 expression in WT cells.  
(B)  MFI of Flt3 expression from CD45.1+ WT competitor and CD45.2+ donor splenic cDCs (left) 
and pDCs (right) (mean ± SD, n = 4-5). 
(C)  Representative histograms of Flt3 expression on competitor and donor CDPs using an 
alternative gating. CDPs were defined as Lin- (B220, CD3, NK1.1, CD11b, Gr-1, Ter119, 
CD11c) Sca-1- IL7R- c-Kitlo CD115+.  
(D)  MFI of Flt3 expression from CD45.1+ WT competitor and CD45.2+ donor CDPs (mean ± SD, n 
= 4-5). 
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Figure 1.9. Downregulation of Flt3 by Flt3-ITD abrogates Flt3L signaling and increases the 
proportion of CD8+-like cDCs in vitro. 
Whole bone marrow from naïve Flt3+/+, Flt3ITD/+, or Flt3ITD/ITD mice was cultured with indicated doses  
of recombinant murine Flt3L for 7 days.  
(A)  Bar graphs depict absolute cell numbers cDCs (defined as CD11c+ MHCII+) and pDCs (defined 
as B220+ Bst2+ CD11b-) shown as mean ± SD from 4 independent experiments. 
(B)  Representative staining profiles of cDC subsets pre-gated on CD11c+ MHCII+. Numbers 
indicate fraction of cells within gated population. 
(C)  Ratio of CD24+ (CD8-like) cDCs to CD11b+ cDCs shown as mean ± SD from 4 independent 
experiments. 









































































































Figure 1.10. Flt3-ITD mostly affects the CD8+ cDC compartment. 
Splenic DC populations from naïve B6xFVB Flt3+/+ or Flt3ITD/+ littermates were enriched from total 
splenocytes by MACS depletion and sorted for RNA extraction. RNA was prepared for hybridization 
onto Affymetrix GenChip Mouse Gene 1.0 ST Array and analyzed for differential gene expression 
using the NIA Array online software tool (ref. 169). Shown are scatter plots of log intensity comparing 
gene expression between Flt3+/+ and Flt3ITD/+ DCs. Red dots signify overexpressed genes and green 
dots signify underexpressed genes upon expression of Flt3-ITD that have more than a two-fold 
change in expression. Cell populations were defined as follows -  CD11b+ cDCs: CD11c+ MHCII+ 
Bst2- CD11b+ CD8!-; CD8+ cDCs: CD11c+ MHCII+ Bst2- CD11b- CD8!+; pDCs: Bst2+ B220+ CD11b-. 






Figure 1.11. Flt3-ITD promotes the expansion of the non-canonical CD8+ cDC subset. 
(A)  Representative staining profiles of CD8+ and CD11b+ cDCs from Cx3cr1GFP/+ Flt3+/+ or 
Cx3cr1GFP/+ Flt3ITD/+ spleen. CD8+ and CD11b+ cDCs are pre-gated on CD11chi MHCII+ cells. 
Numbers show percent of cells within gated population. Histograms show divided subsets of 
CD8+ and CD11b+ cDCs differentiated by GFP expression level. Numbers on histogram show 
proportion of corresponding subset among total CD8+ or CD11b+ cDCs.  
(B)  Frequencies of cDC subsets within CD8+ and CD11b+ cDC populations as shown in (A) (mean 
± SD, n = 5; 6-9 wks old) 
(C)  Fold change in cell frequencies of Cx3cr1GFP/+ Flt3ITD/+ over Cx3cr1GFP/+ Flt3+/+ for each cDC 
subset (mean ± SD, n = 5; 6-9 wks old). To calculate fold change, individual Flt3ITD/+ cell 
frequencies were normalized to the Flt3+/+ average frequency for each subset. Dotted line 
delineates fold change of 1.  
(D)   Cx3cr1GFP/GFP mice were injected i.p. with 3 doses of PBS or 5 µg recombinant Flt3L-Fc every 
3 days. Shown are frequencies of cDC subsets within CD8+ and CD11b+ cDC populations (n = 
2-3; 11 wks old) 
(E)  Fold change in cell frequencies of Flt3L-treated over PBS-treated for each cDC subset as 
described in (D) (mean ± SD, n = 2-3; 11 wks old). To calculate fold change, individual Flt3L-
treated cell frequencies were normalized to the PBS-treated average frequency for each 
subset. Dotted line delineates fold change of 1.  
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Figure 1.12. The non-canonical CD8+ cDC subset expresses PD-L1. 
(A)  Ratio of PDL1+ to CD86+ subsets among CD8+ cDCs in naïve Flt3+/+ or Flt3ITD/+ spleen (mean ± 
SD, n = 4-5; 9-14 wks old). 
(B)  Representative staining profile of CD86 and PD-L1 expression among CD8+ cDC subsets from 
Cx3cr1GFP/GFP splenocytes. Green population represents non-canonical GFPhi CD8+ cDCs, 
while black population represents canonical GFP- CD8+ cDCs.  













































Figure 1.13. Flt3-ITD specifically expands the non-canonical CD8+ cDC subset in Batf3-
deficient mice. 
(A)  Representative staining profiles (left) and bar graph of absolute cell numbers (right) of Flt3+/+ or 
Flt3ITD/+ CD8+ cDC populations in spleen on Batf3+/+ or Batf3-/- background (n = 5; 5-9 wks old). 
Numbers in plots show percent of gated population.  
(B)  Representative staining profiles gated from CD11Chi MHCII+ CD8+ in WT, Batf3-/- Flt3+/+ and 
Batf3-/- Flt3ITD/+ spleen. Numbers indicate percent of cells within gated population.  
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Figure 1.14. Flt3-ITD increases susceptibility to Listeria infection, which requires canonical 
CD8+ cDCs. 
Wild-type or Batf3-deficient Flt3+/+ or Flt3ITD/+ mice were infected with 5 x 103 Listeria monocytogenes. 
Graph shows bacterial titers as colony forming units per gram of spleen 3 days post injection (n= 3-5, 
9-12 wks old).   
































Figure 1.15. Flt3-ITD expands Tregs in the bone marrow. 
The populations of TCR"+ CD4+/CD8+ FoxP3- conventional (Tconv) and TCR"+ CD4+ FoxP3+ 
regulatory (Treg) T cells were analyzed in the bone marrow (BM), spleen (SPL), and lymph nodes (LN) 
by intracellular staining for FoxP3.  
(A)  Frequency (top row) and absolute numbers (bottom row) of Tconv cells in naïve Flt3+/+, Flt3ITD/+, 
or Flt3ITD/ITD mice (mean ± SD, n = 5; 8.5-12.5 wks old).  
(B)  Frequency (top row) and absolute numbers (bottom row) of Treg cells in naïve Flt3+/+, Flt3ITD/+, 
or Flt3ITD/ITD mice (mean ± SD, n = 5; 8.5-12.5 wks old).  
Statistically significant differences are indicated as: * p < 0.05 ; ** p < 0.01 ; *** p < 0.001 
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Figure 1.16. Flt3-ITD expands T cells in a cell-intrinsic manner.  
Lethally irradiated recipients (CD45.1+/CD45.2+) were reconstituted with a 1:1 ratio of CD45.1+ WT 
competitor and CD45.2+ Flt3+/+, Flt3ITD/+, or Flt3ITD/ITD donor bone marrow. Bone marrow (BM), spleen 
(SPL), and lymph nodes (LN) were analyzed 14 weeks after transfer by flow cytometry. The 
populations of TCR"+ CD4+/CD8+ FoxP3- conventional (Tconv) and TCR"+ CD4+ FoxP3+ regulatory 
(Treg) T cells were analyzed by intracellular staining for FoxP3 (mean ± SD, n = 4-5) 
(A)  Percent of Tconv cells out of total WT competitor CD45.1+ cells (white bars) or donor CD45.2+ 
cells (blue bars). 
(B)  Percent of Treg cells out of total WT competitor CD45.1+ cells or donor CD45.2+ cells.  
(C)  Proportion of of Treg cells out of total WT competitor CD45.1+ T cells. 
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Figure 1.17. Flt3-ITD facilitates antigen-driven T cell proliferation.  
Allogeneic mixed leukocyte reactions (MLRs) were performed by using either 50,000 (50k), 25,000 
(25k), or 12,500 (12.5k) CD11c+ enriched splenocytes as stimulators from Flt3+/+ or Flt3ITD/+ B6xFVB 
F1 mice, and incubating them with 50,000 responder bulk T cells isolated from B6 FoxP3GFP spleens 
and lymph nodes labeled with Cell Trace Violet dye (CTV) . Shown are data from 3 individual sets of 
stimulators with the same population of responders. T cells were defined as follows: Tconv - CD45.1- 
TCR"+ CD4+/CD8+ GFP-; Treg- CD45.1- TCR"+ CD4+ GFP+. Bar graphs depict mean ± SD.  
(A)  Absolute numbers of responder CD4+ Tconv, CD8+ Tconv, and Treg populations. 
(B)  Proportion of responder Tregs out of total responder T cells.  
(C)  Representative staining profiles (left) and bar graphs (right) show proportion of proliferative T 
cell populations as measured by dilution of CTV in MLRs. Numbers in FACS plots represent 
percent of proliferating cells that have diluted out CTV.  
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Figure 1.18. Flt3-ITD facilitates homeostatic T cell proliferation.  
Cell Trace Violet (CTV)-labeled T cells from FoxP3GFP mice were transferred into Rag1-deficient Flt3+/
+ or Flt3ITD/+ mice. Adoptively transferred T cell populations were analyzed in the spleens of recipient 
animals 5 days later. Data are pooled from two independent experiments. T cells were defined as 
follows: Tconv - TCR"+ CD4+/CD8+ GFP-; Treg- TCR"+ CD4+ GFP+. 
(A)  Absolute numbers of adoptively transferred CD4+ Tconv, CD8+ Tconv, and Treg populations, 
excluding those that completely diluted out CTV dye due to microbiota antigen stimulation (n = 
10-12; 12-17 wks old).  
(B)  Representative histograms of Tconv cell proliferation as measured by CTV dye from adoptive 
transfers into Rag1-/- recipients. Numbers show proportion of proliferative T cells. T cells that 
completely diluted out CTV dye due to microbiota antigen stimulation were excluded. 
Statistically significant differences are indicated as: * p < 0.05 ; ** p < 0.01 ; *** p < 0.001 
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Figure 1.19. Flt3-ITD favorably reconstitutes Treg populations after Treg depletion.  
Flt3+/+ or Flt3ITD/+ mice carrying the Foxp3DTR-GFP allele were treated for two consecutive days with 
diptheria toxin (DT) to deplete Tregs and analyzed at different time points. Tconv cells were defined as 
TCR"+ CD4+/CD8+ GFP-, while Tregs were defined as TCR"+ CD4+ GFP+.  
(A)  Time course of Treg frequencies out of total lymphocytes in peripheral blood of mice after Treg 
depletion. Red arrows indicate days in which DT treatment was performed. Blood was 
retrieved to monitor Treg populations on day 0, 2, 10, 14, 21, and 28 (mean ± SD,  n = 12-16; 
7-12 wks old).  
(B)  End point analysis of spleen and thymus shown as percentage of Treg out of mature T cells (n 
= 12-16; 7-12 wks old). 
(C)  Percentage of Treg out of mature T cells in spleen and thymus prior to DT administration (n = 4; 
12-20 wks old). 
Statistically significant differences are indicated as: * p < 0.05 ; ** p < 0.01 ; *** p < 0.001 
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Figure 1.20. Flt3-ITD dampens self-reactivity during acute graft-versus-host response.  
30 x 106 WT B6 leukocytes from pooled spleen and lymph node cell suspensions were transferred 
into non-irradiated B6xFVB F1 Flt3+/+ or Flt3ITD/+ recipients. Spleens were analyzed 7 days after 
transfer. Graft T cells were defined as CD45.1- TCR"+ CD4+/CD8+, while host T cells were defined as 
CD45.1+ TCR"+ CD4+/CD8+.  
(A)  Representative staining profiles of graft T cell expansion in Flt3+/+ or Flt3ITD/+ recipients. 
Numbers indicate percent of cells within gated population. 
(B)  Graft T cells presented as frequency of live (left) or absolute numbers (right) in spleen (n = 10, 
9 wks old). 
(C)  Host Tregs presented as percent of total host T cells (n = 8; 7-9 wks old). Data is from a 
separate experiment from data in (B). 
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Figure 1.21. Flt3-ITD dampens self-reactivity during acute-graft-versus-host response in a PD-
L1/PD-1 independent manner.  
30 x 106 WT B6 leukocytes from pooled spleen and lymph node cell suspensions were transferred 
into non-irradiated B6xFVB F1 Flt3+/+ or Flt3ITD/+ recipients. Recipients were treated immediately prior 
and during T cell engraftment every 2-3 days with control IgG or blocking antibodies for PD-L1 or 
PD-1. Spleens were analyzed 7-8 days after transfer. Graft T cells were defined as CD45.1- TCR"+ 
CD4+/CD8+.  
(A)  Graft T cells presented as frequency of live cells in spleen after PD-L1 blockade (n = 4-5, 7-8 
wks old). 
(B)  Graft T cells presented as frequency of live cells in spleen after PD-1 blockade (n = 4, 12-14 
wks old). 
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Figure 1.22. Flt3-ITD cannot ameliorate self-reactivity caused by the absence of Tregs.  
Shown is a Kaplan-Meier survival curve of Treg-deficient FoxP3sf/y Flt3+/+ and FoxP3sf/y Flt3ITD/+ 
littermates. Mice that showed signs of autoimmunity (runting, scaly skin on ears and tails, and 
hunched posture) are presented in this graph. Flt3+/+ : n = 9; Flt3ITD/+ : n = 16.  
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Figure 1.23. Model for the subversion of immunosurveillance during Flt3-ITD leukemogenesis.  
(A)  Flt3-ITD-negative leukemic clones are readily recognized and eliminated by tumor-specific 
cytotoxic lymphocytes. 
(B)  Flt3-ITD-positive leukemic clones give rise to an expanded population of DCs, which indirectly 
promotes the expansion of Tregs that can suppress lymphocyte-mediated cytotoxicity and thus 





















In the previous chapter, we utilized the role of Flt3 as a key regulator of DC development to 
analyze the consequences of aberrant Flt3 activation in the context of leukemia. Here, we again utilize 
Flt3 to reveal novel transcriptional regulators that act in DC development and function. Given its functional 
importance and specific expression in DCs among mature hematopoietic cell types, we employed the 
Immgen database132 to correlate the expression of Flt3 with that of other genes (Figure 2.1). Among the 
genes whose expression correlated with Flt3, only few encoded transcription factors. Among them was 
Cbfa2t3, also known as Mtg16, which has been recently characterized by our group as an important 
regulator of pDC/cDC cell fate decision133. The next two chapters will focus on two additional candidate 
transcription factors whose expression correlates with Flt3 in both murine and human hematopoietic cells. 
In this chapter, we focus on the uncharacterized Myc family transcription factor, Mycl1. While Mycl1 is 
highly expressed in murine DCs, absence of Mycl1 yielded no major differences in DC numbers in 
lymphoid and non-lymphoid tissues. In addition, we found that Mycl1-deficient DCs were fully capable of 
normal proliferation and T cell priming in various conditions of antigen presentation. These results, 








Transcriptional regulation of DC development 
While the use of cell surface markers and adoptive transfers have been essential tools to identify 
the DC lineage, this system is subject to technical caveats and inconsistencies that sometimes create 
more ambiguity than clarity. To accurately define the DC lineage requires identification of regulatory 
elements that functionally mediate developmental transitions, rather than just the use of sometimes 
arbitrary cell surface markers. Therefore, identifying key transcription factors involved in DC development 
will accurately clarify how DC specification occurs within hematopoiesis. Understanding these precise 
mechanisms in vivo will provide an essential guide for harnessing these systems for dendritic cell-based 
immunotherapy. 
 
Regulation of early DC commitment 
All of the transcription factors identified to be required for early DC fate decisions generally result 
in a broad reduction in all DC subtypes along with changes in other hematopoietic lineages upon genetic 
targeting. The first transcription factor proposed to play an important role in DC development is Ikaros, a 
zinc-finger transcription factor previously shown to also be an essential factor for lymphopoiesis. 
Expression of the dominant-negative mutant of Ikaros results in depletion of all DCs, while null mutations 
of Ikaros selectively depletes CD11b+ cDCs and pDCs134,135. Ets-family member PU.1 is another 
transcription factor that has very well-known and broad roles in hematopoiesis. In addition to being 
expressed on HSCs and early myeloid and lymphoid progenitors, PU.1 is expressed on both CDPs and 
cDCs, and to a lesser extent pDCs136. Accordingly, deletion of PU.1 in adult mice results in the drastic 
reduction of all DC subtypes, and has been reported to control the expression of Flt3136. Finally, Gfi-1, 
which has been implicated in HSC homeostasis, T cell development and granulocyte development, has 
also been implicated in DC development, as mice deficient in Gfi-1 show reduced numbers of all DCs137. 
Furthermore, Gfi-1 has been shown to regulate DC development through Stat3. Consistent with this, mice 
deficient in Stat3 also show a depletion of the DC pool138. 
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Regulation of post-commitment DC differentiation 
Described below are several transcription factors that have been identified to control DC subset 
fate, assumingly after the CDP level. These transcription factors are categorized by the DC subsets that 
are most affected by their genetic manipulation: 
CD11b+ (or CD8-) cDCs. NF-kappaB family member RelB was the first transcription factor 
described to affect a distinct subset of DCs. In particular, disruption of the RelB locus results in an overall 
reduction in thymic DCs (which was shown to be driven by non-hematopoietic cells) and a selective 
reduction in splenic CD8- cDCs139,140. Meanwhile, CD8+ cDC and pDC numbers were unaffected and were 
still able to stimulate T cell responses and produce IFN" ex vivo, respectively140,141. The second 
transcription factor implicated in CD11b+ cDC development is interferon-regulatory factor Irf4. Similar to 
phenotypes found in RelB deficiency, loss of Irf4 results in a specific reduction in splenic CD11b+ CD4+ 
cDCs with no changes in cell numbers for CD8+ cDCs and pDCs142. Additionally, GM-CSF-derived DCs 
from Irf4-/- bone marrow are unable to induce antigen-stimulated T cells to produce IL-2142. Notch signaling 
transcription factor RBPJ has also been implicated in regulating the CD11b+ cDC subset, however RBPJ 
seems to promote the survival and homeostasis of CD11b+ cDCs, as opposed to their development143. 
CD8+ cDCs. Despite being expressed in both CD8+ and CD11b+ cDCs, deletion of Batf3 leads to 
a depletion specifically in the CD8+ cDC subset, and not in precursor DC populations like pre-DCs17,21. 
Consequently, mice that lack Batf3 show a pronounced inability to cross-present to CD8+ T cells17. 
Interestingly, the residual population of CD8+ cDCs that remains in these mice consists solely of the non-
canonical CD8+ cDCs that lack several features of the canonical counterparts20. Two other proteins, 
inhibitory helix-loop-helix transcription factor Id2 and interferon-regulatory factor Irf8, have also been 
implicated in CD8+ cDC lineage specification, but also have an indirect or dual role in the pDC lineage. 
Id2 is expressed on all cDCs, more so in CD8+ than CD11b+ subsets, but is not expressed on precursor 
cells133,144.  Accordingly, mice that lack Id2 show a significant reduction in CD8+ cDCs but not CD11b+, 
whereas pDCs show an increase in numbers, in agreement with the fact that forced expression of Id2 
leads to a decrease in pDCs in human cells145. Irf8 is expressed highly in CD8+ cDCs and pDCs but not in 
CD11b+ cDCs146. Unlike in Id2 knockout models, depletion of Irf8 leads to significant reductions in both 
CD8+ cDCs and pDCs, while leaving CD8- cDCs relatively intact147. 
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pDCs. Our lab has identified E-protein E2-2 as a specific and crucial regulator of pDC fate. The 
long isoform of E2-2 is specifically expressed in pDCs, but not cDCs (L. Grajkowska, unpublished). 
Complete deletion of E2-2 in adult mice leads to a complete loss of pDCs in bone marrow and spleen, 
and haploinsufficiency of E2-2 in mice is enough to impair pDC development27. E2-2 seems to regulate a 
cohort of transcription factors that have been shown to govern pDC fate decisions, such as Irf8 (as 
described above), Bcl11a, and Spi-B27,148. Adult mice deficient in Bcl11a within the hematopoietic system 
show decreases in pDCs but normal levels of cDCs and CDPs, while Spi-B has been shown to be an 
important factor in generating human pDCs and plays a role in murine pDC development and function149-
151. Interestingly, E2-2 also works to repress cDC fate by suppressing Id2 expression in complex with Eto 
family protein Mtg16133. 
 
While the last decade and a half has unveiled a number of transcriptional regulators involved in 
various aspects of DC development, no transcription factors have been identified that specifically promote 
cDC fate over pDC fate. Recently, Zbtb46 was found to be specifically expressed in the cDC 
lineage152,153. While it may become a useful tool for cDC identification in vivo, it is clear the transcription 
factor itself is largely dispensable for DC development154. Therefore, our complete knowledge of how 
exactly the bifurcation from the CDP level occurs still remains unclear. 
 
Mycl1/L-myc 
Mycl1 was originally discovered as an amplified gene in human small cell lung carcinoma155. 
Mycl1 is a member of the Myc oncogene family, which includes other more recognized members c-Myc 
and N-Myc. Similarly to its other family members, Mycl1 encodes three exons and contains a conserved 
carboxyl-terminal basic-helix-loops-helix (bHLH) zipper domain that interacts with other small bHLH 
proteins, thus allowing the heterodimer to bind to DNA E-box sequences156,157. While structurally similar, 
Mycl1 expression during development and its activity differ significantly from the other members in a 
context-dependent manner. For example, the in vitro transforming abilities of Mycl1 are weaker than that 
of c-Myc in rat fibroblasts157. In vivo, Mycl1 overexpression under the control of an immunoglobulin 
enhancer leads to T cell lymphoma, as opposed to B cell malignancies seen with c-Myc or N-Myc158. 
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Furthermore, in stark contrast to mice deficient in c-Myc, mice that lack Mycl1 show no apparent 
phenotype and are viable and fertile159. 
Most studies on Mycl1 have focused on its role in cancer, while its role in the steady state still 
remains to be determined. Mycl1 is highly expressed in the developing murine brain, and to a lesser 
extent the developing kidney, lung, intestine, and adult intestine and lung160. While Mycl1 was initially not 
detected in the spleen, a closer look at the various cell types within the hematopoietic system shows that 
Mycl1 is highly and specifically expressed in DCs in both mice and human132,161,162. Given the unique 
expression pattern of Mycl1 and its relation to a family that has significant roles in proliferation, growth, 






Mycl1-/- mice show normal DC numbers 
In order to investigate the potential role of Mycl1 in vivo, we analyzed mice in which all three 
exons of the Mycl1 gene was removed. As reported before using a different mouse model159, no gross 
abnormalities were observed and mice were viable and fertile. Given the specific expression pattern of 
Mycl1 in DCs, we analyzed DC populations in the spleen, a lymphoid organ that has an abundant 
representation of DCs. Analysis of DC populations in the spleen showed normal cell numbers and 
frequencies for both types of cDCs as well as pDCs (Figure 2.2A-D). The only notable characteristic was 
a very slight downregulation of CD8" expression in CD11b- cDCs, however this change was not 
significant (2.2A,E). Analysis of other lymphoid organs like the bone marrow and skin-draining lymph 
nodes also showed normal frequencies of both cDCs (Figure 2.3A) and pDCs (Figure 2.3C). Overall, 
there were no overt differences in DC populations in the steady state. This was true also for mice in which 
Mycl1 was specifically deleted in the DC compartment using the CD11c-Cre mouse strain (Figure 2.2F-G; 
Figure 2.3B,D). 
While there did not seem to be drastic differences in the spleen, we investigated analogous DC 
populations in nonlymphoid tissues. Tissues like the intestine, lung, and skin constantly encounter foreign 
material, and therefore may highlight any development or functional phenotype not seen in steady-state 
lymphoid tissues. Analysis of the lamina propria of small intestine showed a slight overall decrease in 
cDC populations mainly in the small intestine (Figure 2.4A), but not in the large intestine (Figure 2.4B) or 
mesenteric lymph nodes (Figure 2.4C). Closer analysis of the subpopulations of cDCs showed a slight 
reduction in the proportion of CD103+ cDCs in the small intestine and large intestine, but not in CD11b+ 
CD103+ cDCs. In contrast, analysis of epidermal Langerhan cells (Figure 2.5A), dermal cDCs (Figure 
2.5B), migratory cDCs in skin-draining lymph nodes (Figure 2.5C), and lung cDCs (Figure 2.6A-B) 
showed normal DC numbers and cDC subset proportions. Overall, we conclude that mice deficient in 
Mycl1 quantitatively display a normal DC phenotype in both lymphoid and nonlymphoid tissues. 
 
Mycl1-/- mice show normal DC development and proliferation 
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Because mature DC numbers looked normal in the steady state, we decided to test the function 
of early DC progenitors by inducing DC development in vitro and in vivo. Flt3L is a key cytokine required 
for the development of DCs and administration in vitro and in vivo is sufficient to drive early progenitors to 
produce DCs69. To this end, we tested DC development in vitro by first culturing whole bone marrow 
suspensions from WT or Mycl1-/- mice in Flt3L-rich supernatant obtained from a Flt3L-secreting B16 
melanoma cell line. As seen in Figure 2.7, Mycl1-/- bone marrow was able to produce a comparable 
proportion and number of cDCs and pDCs. Moreover, these DCs looked phenotypically similar by cell 
surface markers. We also administered Flt3L in vivo to test whether presence of other extracellular cues 
may affect Mycl1-/- DC development. Similar to what we see in vitro, Mycl1-/- mice were completely 
capable of driving DC development in vivo and generated the same frequencies of cDCs and pDCs 
compared to WT in the spleen (Figure 2.8A-B) and small intestine lamina propria (Figure 2.8C-D). This 
was also true for the bone marrow, skin-draining lymph nodes, and mesenteric lymph nodes (data not 
shown). Thus, Mycl1 does not affect Flt3L-induced DC development in vitro or in vivo. 
In vivo, IL-12 administration increases the number of CD8+ cDCs in WT mice and is sufficient to 
drive regeneration of CD8+ cDCs in Batf3-/- mice that normally lack these cells in the steady state163. Thus, 
as another means to drive DC development in vivo, we also administered murine IL-12 to WT or Mycl1-/- 
mice and analyzed DC subsets in the spleen. As expected, we saw an increase in CD8+ cDCs in the 
spleens of IL-12-treated WT mice versus PBS-treated (Figure 2.9B). We also saw an increase CD11b+ 
cDCs (Figure 2.9B) along with an overall increase in cDC numbers (Figure 2.9A). However, Mycl1-/- mice 
responded similarly to WT mice, indicating that there was no defect in IL-12-induced DC development. 
The same was true for the bone marrow (data not shown). 
While overall DC numbers did not change, it may be possible that Mycl1 affects mature DC 
turnover and that earlier progenitors are compensating for this change. Therefore, we tested the 
proliferation of mature DCs by measuring BrDU incorporation shortly after the initial pulse. As described 
before, splenic CD8+ cDCs showed the highest proliferation rate compared to other DCs, while pDCs 
show the lowest (Figure 2.10). Comparison of WT and Mycl1-/- DC populations showed no difference in 
BrDU uptake. Thus, Mycl1 does not control the proliferation of DCs. 
 
 85 
Mycl1-/- DCs show normal T cell responses 
While Mycl1-deficient DCs do not seem to be phenotypically different from their WT counterparts, 
these observations do not preclude the possibility that Mycl1 may govern the function of these DCs. 
Because most of the subtle changes that we saw were restricted to the CD8+ and CD8+-like cDCs, we 
sought to test their cross-presentation ability in vivo. Using OVA protein as an antigen source, we injected 
apoptotic, antigen-pulsed BALB/c splenocytes into WT or CD11c-Cre Mycl1fl/fl 129 recipients and 
quantified the frequency of OVA-specific CD8+ T cells one week later. Because BALB/c and 129 express 
different MHC I haplotypes, only CD8+ cDCs from the recipient and not the donor are able to present to 
129 T cells. Flow cytometric analysis of recipient spleens showed a trend of fewer antigen-specific CD8+ T 
cells generated, however this slight reduction was not significant (Figure 2.11). 
In addition to using OVA, we also measured cross-presentation under more physiological 
conditions of a viral and bacterial infection. WT or CD11c-Cre Mycl1fl/fl mice were infected with influenza 
virus and tetramer-specific CD8+ T cells in the lung, mediastinal lymph node, and spleen were measured 
1 week later. As shown in Figure 2.12A, recipients show no change in virus-specific T cell numbers, nor 
did they show a significant change succumbing to the disease, as measured by weight loss (2.12B). WT 
or Mycl1-/- mice were also infected with OVA-expressing Listeria monocytogenes and measured for OVA-
specific T cell responses 1 week later. Mycl1-/- mice exhibited no difference in proportion or number of 
tetramer-positive CD8+ T cells (Figure 2.12C). Overall, we conclude that mice deficient in Mycl1 still retain 
a normal ability to cross-present to CD8+ T cells. 
 
Mycl1-/- CD8+ cDC gene expression is similar to Mycl1+/+ 
Because we did not see any significant differences in DC development or DC function, we 
investigated whether there were changes in the genetic program of Mycl1-/- DCs, again focusing on CD8+ 
cDCs. Hence, we performed microarray analysis on sorted WT and Mycl1-/- splenic CD8+ cDCs. As 
shown in Figure 2.13, surprisingly little difference in expression pattern was seen between WT and Mycl1-
/- splenic CD8+ cDCs. Among the genes that were downregulated, Mycl1 came up as the top hit, 
validating the gene targeting. Genes that were upregulated upon Mycl1 encoded mainly immunoglobulin 
proteins. Of note, Mfsd2, which is a neighboring gene of Mycl1, was also upregulated, suggesting that the 
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deletion of the Mycl1 locus may have disrupted negative regulatory elements of Mfsd2 transcription. 
Nevertheless, aside from Mycl1 itself, the overall genetic landscape of Mycl1-deficient splenic CD8+ cDCs 
showed very little difference compared to that of WT splenic CD8+ cDCs. 
Overall, these results support the conclusion that Mycl1 does not impair the development, 




Mycl1 is dispensable for DC development and function 
Our current knowledge on how an early hematopoietic progenitor commits to the DC fate is still 
under active investigation. While several transcription factors have been identified to be crucial for DC 
development, we have yet to identify a single molecule that specifically regulates the cDC fate. Zbtb46 
was indeed a prime candidate given its specific expression in pre-DCs and mature cDCs. Unfortunately 
Zbtb46-deficient cDCs seem to develop normally, indicating that it mostly does not play a role in cDC 
development152,153. Similar to Zbtb46, Mycl1 becomes increasingly expressed in the cDC lineage, instead 
starting from the CDP, and thus, was a potential candidate to regulate cDC fate decisions. However, our 
work has shown that Mycl1 is entirely dispensable for DC development and function. Analysis of DC 
proportions in spleen, skin-draining lymph nodes, epidermis, dermis, lung, small intestine LPL, large 
intestine LPL, and mesenteric lymph nodes show normal phenotypes as in WT mice. The only potential 
difference was in CD8+ and CD8+-like cDCs, and still the phenotype was quite subtle. Functionally, Mycl1-
/- CD8+ cDCs are capable of cross-presenting antigen from apoptotic cells, viral antigen, and bacterial 
antigen to CD8+ T cells, with some variation between assays. Finally, the genomic expression pattern of 
Mycl1-/- CD8+ cDCs only narrowly differs, with the biggest change in expression being in Mycl1 
transcripts.  
 
Discrepancies on the functional role of Mycl1 in DCs 
Another group has published work on the role of Mycl1 in dendritic cell development using a GFP 
knockin/knockout model of Mycl1164. While our conclusion that Mycl1 does not play a role in DC 
development corroborates with their results, our studies in the functional role of Mycl1 in DCs do not 
agree. Their microarray analysis performed on steady-state CD8+ cDCs revealed a select number of 
Mycl1 targets involved in cell proliferation and apoptosis, and accordingly Mycl1-deficient cDCs showed a 
reduction in BrdU uptake. This is in contrast to our results, in which very few genes were downregulated 
and no difference was seen in proliferation. Additionally, KC et al show a deficiency in T cell priming 
during L. monocytogenes infection, along with protection against a lethal infection. This contradicts our 
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results, in which we do not see a difference in T cell priming under various conditions, including L. 
monocytogenes infection. 
Several considerations can be taken into account in order to reconcile this clear discrepancy. The 
foremost difference between our studies and the studies of KC et al is the mouse model and gene 
targeting. Our mouse model deletes the entirety of the Mycl1 gene: exon 1, an untranslated region that 
may have regulatory elements in it; exon 2, which encodes the transactivation domain; and exon 3, which 
encodes the DNA/protein-binding bHLH and leucine zipper domain165. The mouse model of KC et al 
targets only the first coding exon (exon 2). Although unlikely, it is possible that a protein containing only 
exon 3 may have been transcribed and generated either dominant negative isoform or protein that 
aberrantly blocks DNA binding. Depending on the epitope of the antibody and the target sequence of the 
hybridized probe, this aberrant protein may have remained undetected and therefore interpreted as 
deficient in Mycl1 protein. Another main difference between our mouse models is the strain background. 
While our model remained on a 129 background, several experiments done by KC et al were done on 
C57BL/6, including the proliferation experiments. Indeed, mouse strain backgrounds do make a 
difference in phenotype in certain cases. For example, C57BL/6 are known to be more resistant to L. 
monocytogenes infection than other strains166. Furthermore, steady-state distributions of splenic WT 129 
and C57BL/6 are slightly different, with the former often containing fewer CD8+ cDCs than the latter (data 
not shown). Therefore, it may be possible that compensatory mechanisms in the 129 background not 
present in the C57BL/6 strain may have masked the phenotype that KC et al see. Technical differences 
may also account for the disparity in results specifically in the role of Mycl1 in T cell priming. In particular, 
we measured the priming of endogenous T cells, rather than transgenic OT I cells, which are particularly 
sensitive to OVA stimulation. Therefore, subtle differences that may not have reached significance in our 
hands may have been amplified using OT I cells. However, the most likely explanation for the lack of 
phenotype observed in our model is the genetic redundancy of Myc transcription factors. KC et al, while 
describing a reduced expression of c-Myc expression in mature DCs, still demonstrate some basal 
expression in mature DCs, especially in cDCs. It is likely that this basal expression of c-Myc is sufficient to 
compensate for lack of Mycl1 expression, and that abrogation of both Myc transcription factors would 
reveal the function of Mycl1 in cDCs. 
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Other potential roles of Mycl1 in DC biology 
KC et al provide additional evidence for other roles that Mycl1 may play in DC function that we did 
not address. For example, they show that Mycl1 protein is maintained during inflammatory conditions and 
generally downregulates a genetic program induced by GM-CSF signaling. Additionally, they provide 
evidence for a potential connection with Irf8 regulation. The most striking phenotype of their Mycl1-
deficient model is the resistance to a lethal infection by L. monocytogenes, which was due to the 
reduction of intracellular cell growth, and not due to reduced bacterial capture or DC viability, despite their 
claim that Mycl1 controls proliferation and survival of DCs. These observations collectively paint a very 
broad but disjointed role for Mycl1, which may mirror the broad regulatory role that other Myc family 
members encompass167. Nevertheless, it is clear from our studies and the studies of KC et al that Mycl1 
alone, like Zbtb46, is dispensable for DC development in the steady state, and that the search for the 
cDC-specific transcription factor continues on. 
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MATERIALS AND METHODS 
 
Animals 
Mycl1fl/fl mice were made by Robert Eisenman and acquired from Jackson. To generate germ-line 
deletions, Mycl1fl/fl mice were bred to a Prm-Cre strain168 that deletes in the male germline. To generate 
DC-specific deletion, Mycl1fl/fl mice were bred to Itgax-Cre (CD11c-Cre) developed in our lab143. All mice 
were on 129 backgrounds. BALB/c mice were acquired from Taconic. All animal studies were performed 




Spleen, thymus, and lymph nodes were minced and pressed through a nylon cell strainer to yield single 
cell suspensions and then subjected to red blood cell (RBC) lysis before being filtered. Bone marrow was 
prepared by flushing femurs and tibias with phosphate buffer saline (PBS) using a 27-gauge needle 
before RBC lysis. For lymphoid organ DC analysis, organs were digested with collagenase D (1 mg/mL) 
and DNAseI (20µg/mL) in for 30-60 min at 37°C prior to generating cell suspensions. Small intestine 
lamina propria lymphocytes were prepared as described before131. For epidermis/dermis DC analysis, 
dorsal and ventral earflaps were “floated” on HBSS and 4 u/mL Dispase for 90 min at 37°C to separate 
dermis and epidermis. Epidermis and dermis were minced and digested with collagenase D (400 u/mL) 
and DNaseI (100 µg/mL) for 45 min at 37°C with an additional 4 u/mL Dispase for the dermis. EDTA was 
added, and tissues were pressed into a cell strainer to yield single cell suspensions. For DC lung 
analysis, lungs were perfused with PBS and digested with collagenase D (400 u/mL). DC preparations 
were performed by Aleksey Chudnovskiy and Brandon Hogstad from the lab of Miriam Merad at Mount 
Sinai School of Medicine (NY, New York). 
 
Flow cytometry 
Cells were stained with the following fluorochrome- or biotin-conjugated antibodies from eBioscience or 
as indicated: anti-CD11c (N418), MHC II (M5/114.15.2), CD11b (M1/70), CD8! (53-6.7), CD103 (2E7), 
 91 
B220 (RA3-6B2), mPDCA-1/Bst2 (Miltenyi Biotec), CD317/PDCA/Bst2 (Biolegend clone 927), CD24 
(M1/69), TCR" (H57-597), CD3 (17A2), CD4 (RM4-5 and GK1.5), CD44 (IM7), F4/80 (BM8), and CD45 
(30-F11). Cell acquisition was done on LSR II (BD Biosciences) using FACSDiva (BD Biosciences) and 
analysis was done on FlowJo (Tree Star). DC analyses were performed by Aleksey Chudnovskiy and 
Brandon Hogstad from the lab of Miriam Merad at Mount Sinai School of Medicine (NY, New York). 
 
In vitro BM-derived DC cultures 
Bone marrow cells were harvested as described above. RBC-lysed cells were plated in triplicates in a 24-
well plate at 2 x 106 per well in DMEM/10% FCS and 20% supernatant from cultured Flt3L-secreting B16 
melanoma cell lines. Suspension and adherent cells were harvested after 8 days and triplicates were 
pooled for counting and flow cytometric analysis. 
 
Flt3L administration 
Mice were injected intraperitoneally (i.p.) with 10 µg recombinant Flt3L-Fc (LakePharma) every 3 days 
(d0, d3) and analyzed on day 6 after initial treatment. Spleens, bone marrow, skin-draining lymph nodes, 
mesenteric lymph nodes, and small intestine were harvested for flow cytometry and prepared as 
described above for DC analysis. 
 
IL-12 administration 
Mice were injected i.p. with PBS or 0.5 µg murine IL-12 (PeproTech) for four consecutive days and 
analyzed 6 days after initial treatment. Spleens and bone marrow were harvested for flow cytometry and 
prepared as described above for DC analysis. 
 
BrDU incorporation 
For BrDU labeling, mice were injected i.p. with 2 mg of BrDU (Sigma) or PBS and analyzed 4 hours later 
for flow cytometry. Spleens were prepared, as described above, and single cell suspensions were stained 
for cell surface markers, fixed, permeabilized, and stained for BrDU using the APC BrDU Flow Kit from 
BD Biosciences as per manufacturer’s instructions. 
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In vivo cross presentation assay 
Chicken ovalbumin protein (Sigma) was hypertonically pulsed into BALB/c (H-2d) splenocytes and lymph 
node cells. Briefly, cells were incubated with a hypertonic solution of 10% polyethylene glycol, 0.5 M 
sucrose, 10 mM HEPES, and 10 mg/mL ovalbumin in RPMI buffer for 10 minutes at 37°C and then 
immediately flushed with a hypotonic solution of 40% water in RPMI. Cells were incubated for 2 min at 
37°C and washed with cold PBS. Cells were irradiated with 2000cGy and injected into Mycl1fl/fl or CD11c-
Cre Mycl1fl/fl (H-2b) at a dose of ~40 x 106 cells per recipient. 
 
Influenza infection 
Mice were infected with a sublethal dose (500 TCID50) of PR8 H1N1 virus. Spleens, lungs, and 
mediastinal lymph nodes were analyzed 7 days later for T cell analysis. Antigen-specific CD8+ T cells 
were identified using a mix of PE-conjugated hemagluttinin (HA) or polymerase (PA) peptide-loaded MHC 
I tetramer complexes (MBL International). Infection, cell preparations, and flow cytometry were performed 
in collaboration with Damian Turner from the lab of Donna Farber at Columbia University Medical Center. 
 
Listeria monocytogenes infection 
Mice were infected with 5 x 104 CFU of Listeria monocytogenes expressing OVA in PBS and injected 
intravenously. Spleens were analyzed 8 days later for T cell analysis. Antigen-specific CD8+ T cells were 
identified using a PE-conjugated SIINFEKL peptide-loaded MHC I tetramer complexes (Beckman 
Coulter). Infection was performed in collaboration with Simone Nish from the lab of Steven Reiner at 
Columbia University Medical center. 
 
Gene expression analysis 
Splenocytes from Mycl1+/+ or Mycl1-/- were depleted of lymphoid and erythroid cells by negative selection 
using MACS columns and the following biotinylated antibodies: anti-CD19 (eBio1D3), Gr-1 (RB6-8C5), 
CD3 (17A2), Ter119 (TER-119), CD49b (DX5). CD8+ cDCs were sorted as CD11chi MHCII+ CD11b- 
CD8"+ Bst2- B220- on BD Influx (BD Biosciences) and RNA was isolated by Trizol (Life Technologies) 
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extraction per manufacturer’s instructions. Samples were reverse-transcribed, labeled, and hybridized 
onto GeneChip Mouse Gene 1.0 ST array (Affymetrix) according to manufacturer’s instructions. RMA-
normalized gene expression values were analyzed using NIA Array software169. 
 
Statistical analysis 
Statistical significance was estimated with unpaired, two-tailed Student’s T test, unless otherwise 
indicated. 
CHAPTER II FIGURES 
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Figure 2.1. Genes correlated with Flt3 expression. 
Shown are murine genes found to be correlated with the expression pattern of Flt3 within the 
hematopoietic system using the Immgen database (ref. 132). Genes outlined in red indicate 
described or putative transcription factors. Distance of gene from center indicates tightness of 
correlation, with the closest genes being more tightly correlated. Correlation was calculated using 
Pearson correlation. 
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Figure 2.2. Mycl1-deficient mice show normal DC numbers in the spleen. 
(A)  Representative staining profiles of splenic cDC populations in naïve Mycl1+/+ (WT) and Mycl1-/- 
(KO) . CD11b+ and CD8+ cDC populations are labeled. Numbers in FACS plots indicate 
percent of gated population. Mean fluorescent intensity (MFI) numbers above histogram 
indicates CD8! MFI among CD11b- population. Percentages in histogram indicate proportion 
of CD8+ cDCs. 
(B)  Representative staining profiles of splenic pDC populations in naïve Mycl1+/+ (WT) and Mycl1-/- 
(KO) mice. 
(C)  Absolute numbers (top row) and frequencies (bottom row) of total cDCs and cDC subsets as 
identified in (A) (mean ± SD, n = 4).  
(D)  Absolute number (top row) and frequency (bottom row) of pDCs identified in (B) (mean ± SD, n 
= 4). 
(E)  Pair-wise comparison of CD8! MFI among CD11b- population, as described in (A). Statistics 
were analyzed using paired two-tailed Student’s t-test.  
(F)  Representative staining profiles of splenic cDC populations in naïve Mycl1fl/fl (WT) and CD11c-
Cre+/- Mycl1fl/fl (CKO) mice. Numbers in FACS plots indicate percent of gated population. Mean 
fluorescent intensity (MFI) numbers above histogram indicates CD8! MFI among CD11b- 
population. Percentages in histogram indicate proportion of CD8+ cDCs. Data is representative 
of 3 experiments. 
(G)  Representative staining profiles of splenic pDC populations in naïve Mycl1fl/fl (WT) and CD11c-



























































































































































































































































Figure 2.3. Mycl1-deficient mice show normal DC numbers in other lymphoid tissues.  
(A)  Representative staining profiles of cDC populations in Mycl1+/+ (WT) and Mycl1-/- (KO) bone 
marrow and skin-draining lymph nodes (inguinal, brachial, axillary, cervical). Numbers indicate 
percent of gated population. Resident cDCs are identified as CD11chi MHCII+ and migratory 
cDCs as CD11c+ MHCIIhi. CD11b+ and CD11b- cDCs are shown. Data is representative of 2-3  
experiments. 
(B)  Representative staining profiles of cDC populations in Mycl1fl/fl (WT) and CD11c-Cre+/- Mycl1fl/fl 
(CKO), as in (A). Bone marrow data is representative of one experiment, while lymph node 
data is representative of 3 independent experiments. 
(C)  Representative staining profiles of pDC populations in Mycl1+/+ (WT) and Mycl1-/- (KO) bone 
marrow and skin-draining lymph nodes. Data is representative of 2-3 independent 
experiments. 
(D)  Representative staining profiles of pDC populations in Mycl1fl/fl (WT) and CD11c-Cre+/- Mycl1fl/fl 
(CKO). Bone marrow data is representative of one experiment, while lymph node data is 
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Figure 2.4. Mycl1-deficient mice show slight reduction of DC numbers in the small intestine. 
(A)  Representative staining profile of cDCs isolated from small intestine lamina propria 
lymphocytes (LPL) of Mycl1+/+ (WT) and Mycl1-/- (KO) mice. Plots are pre-gated on CD45+ 
cells. Numbers show percent of gated population. Data is representative of 2 independent 
experiments. 
(B)  Representative staining profiles of cDCs isolated from large intestine LPL as in (A). 
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Figure 2.5. Mycl1-deficient mice show normal DC numbers in the dermis and epidermis.  
(A)  Representative staining profiles of epidermal Langerhan cells (LC) in Mycl1+/+ (WT) and 
Mycl1-/- (KO) mice. Plots are pre-gated on CD45+ cells. Numbers show percent of gated 
population as mean ± SD, n = 2-3. 
(B)  Representative staining profiles of dermal DCs in WT and KO mice. Plots are pre-gated on 
CD45+ MHCII+ F4/80- SSClo cells. Numbers show percent of gated population as mean ± SD, n 
= 2-3. 
(C)  Representative staining profiles of migratory DCs in WT and KO skin-draining lymph nodes 
(brachial, inguinal, and popliteal). Plots are pre-gated on CD11c+ MHCIIhi cells. Three 
populations of DCs are shown and are marked in WT graphs: migratory CD103+ cDCs (i), 
migratory LCs (ii), and migratory CD11b+ cDCs (iii). Numbers show percent of gated 
population as mean ± SD, n = 2-3. 
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Figure 2.6. Mycl1-deficient mice show normal DC numbers in the lung. 
(A)  Representative gating strategy for identifying CD103+ and CD11b+ cDC populations in the lung. 
(B)  Representative staining profiles of lung cDCs in Mycl1+/+ (WT) and Mycl1-/- (KO) mice. Plots are 
pre-gated as shown in (A). Numbers show percent of gated population as mean ± SD, n = 2-3. 


































Figure 2.7. Mycl1-deficient mice show normal DC numbers in Flt3L-driven development in 
vitro.  
Whole bone marrow from naïve Mycl1+/+ (WT) and Mycl1-/- (KO) mice was cultured 20% Flt3L-rich 
supernatant for 8 days. Shown are representative staining profiles of cDC subsets pre-gated on 
CD11c+ MHCII+ (left) and pDC subsets pre-gated on B220+ cells. Numbers on plot indicate fraction of 
cells within gated population. Numbers below are absolute total live cell numbers from each 
condition. 
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Figure 2.8. Mycl1-deficient mice show normal DC numbers in Flt3L-driven development in 
vivo.  
Mycl1+/+ (WT) and Mycl1-/- (KO) mice were injected intraperitoneally with 2 doses of 10 µg of Flt3L 
every three days and analyzed 6 days after initial treatment.! 
(A)  Representative staining profiles of cDCs isolated from spleens of WT and KO mice. Numbers 
show percent of gated population. 
(B)  Frequencies of total cDC (top) and cDC subset (bottom) expansion, as gated in (A). CD11b- 
CD8- population was not included in analysis. Graphs are shown as mean of 3 animals per 
condition. 
(C)  Representative FACS plots of cDCs isolated from small intestine lamina propria lymphocytes 
(LPL) of WT and KO mice. Numbers show percent of gated population. 
(D)  Frequencies of total cDC (top left) and cDC subset (top right, bottom) expansion, as gated in 
(C). CD11b- CD103- population was not included in analysis. Graphs are shown as mean of 3 
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Figure 2.9. Mycl1-deficient mice show normal DC numbers in IL-12-driven development in 
vivo.  
Mycl1+/+ (WT) and Mycl1-/- (KO) mice were injected intraperitoneally with PBS or 0.5 µg of murine 
IL-12 once a day for 4 days and analyzed 6 days after initial treatment.! 
(A)  Frequencies of total cDC from WT and KO spleen, gated as CD11chi MHCII+. Graphs are 
shown as mean of 2-3 animals per condition. 
(B)  Frequencies of cDC subsets from WT and KO spleen, pre-gated as CD11chi MHCII+. Graphs 
are shown as mean of 2-3 animals per condition. 
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Figure 2.10. Mycl1-deficient mice show normal proliferation rates. 
Mycl1+/+ (WT) and Mycl1-/- (KO) cells were labeled in vivo by injecting mice intraperitoneally with 2 mg 
of BrDU. Mice were sacrificed 4 hours later and spleens were analyzed for BrDU incorporation. 
Shown are graphs depicting the percentage of cells that have incorporated BrDU within each 
indicated cell population. Graphs are shown as mean of 5 animals per condition. 
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Figure 2.11. Mycl1-deficient mice show normal cross-presentation of antigen from apoptotic 
cells. 
Apoptotic ovalbumin (OVA)-pulsed BALB/c cells were injected into Mycl1fl/fl (WT) and Mycl1fl/fl (CKO) 
and analyzed 7 days after transfer for OVA-specific CD8+ T cells.! 
(A)  Representative staining profiles of CD8+ T cells from immunized mice. Number in FACS plot 
indicates percent of tetramer-positive (and thus OVA-specific) cells out of total CD8+ T cells in 
spleen.  
(B)  Percent of tetramer-positive cells out of total CD8+ T cell population (left) and absolute 
numbers (right) of tetramer-positive cells in splenic leukocytes. Graphs are shown as mean of 
4 animals per condition. 
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Figure 2.12. Mycl1-deficient mice show normal cross-presentation during viral and bacterial 
infections. 
(A)   Mycl1fl/fl (WT) and Mycl1fl/fl (CKO) mice were infected with a sublethal dose of influenza virus 
and analyzed after 7 days for viral antigen-specific CD8+ T cells. Shown are percentages of 
tetramer-positive (viral antigen-specific) cells out of total CD8+ T cells within lungs, spleens, 
and mediastinal lymph nodes. Cells were gated on CD8+ CD11a+ tet+. Graphs show data as 
mean from 3 animals per condition.  
(B)  Time course of weight loss of mice in (A) after infection. 
(C)   Mycl1+/+ (WT) and Mycl1-/- (KO) mice were infected with Listeria monocytogenes expressing 
OVA at a sublethal dose of 5 x 104 CFU and analyzed after 8 days for SIINFEKL tetramer-
positive CD8+ T cells. Shown are percentages of tetramer-positive cells out of total CD8+ T 
cells (left) and absolute numbers of tetramer-positive CD8+ T cells (right). Cells were gated on 
B220- TCRb+ CD8+ CD44+ tet+. Graphs show data as mean from 4-5 animals per condition. 
 Influenza infection and cell analysis were performed by D. Turner. Listeria infection was 
performed by S. Nish. 
116 
Weights CKO
















































































































WT       CKO 































WT       CKO 




































































Figure 2.13. Mycl1-deficient CD8+ cDCs show minimal change in gene expression. 
Mycl1+/+ and Mycl1-/- splenic DCs were enriched from total splenocytes by MACS depletion and CD8+ 
cDC populations were sorted for RNA extraction. RNA was prepared for hybridization onto Affymetrix 
GenChip Mouse Gene 1.0 ST Array and analyzed for differential gene expression using the NIA Array 
online software tool (ref. 169). Shown is a scatter plot of log intensity comparing gene expression 
between Mycl1-deficient and wild-type mice. Red dots signify overexpressed genes and green dots 
signify underexpressed genes upon Mycl1 depletion that have more than a two-fold change in 
expression. Highlighted genes are indicated. False discovery rate was set at <0.05. 
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THE ROLE OF EVT6 IN DENDRITIC CELL AND MONOCYTE DEVELOPMENT, 





In this last chapter, we focus on our second candidate transcription factor whose expression 
pattern correlated with that of Flt3, the Ets-family protein Etv6. Its closest ortholog in Drosophila is an 
important regulator of cell differentiation during development, and recently Etv6 has been shown to have 
a role in hematopoietic cell differentiation. In addition to its well-documented expression in hematopoietic 
stem cells (HSC) and progenitors, we observed that Etv6 is prominently expressed in DCs and 
monocytes136.  In accordance to its role in HSC biology, Etv6 is well known in the hematopoietic cancer 
field, as multiple genes are translocated onto its locus, forming fusion oncoproteins that deregulate 
signaling or transcription. However, a role for Etv6 in DCs and monocytes has yet to be determined. This 
section focuses on the effect of Etv6 deletion in the DC and monocyte compartment, and describes 
several alterations in their development, homeostasis, and differentiation. In addition, we provide 
evidence that implicates Etv6 in the suppression of interferon signaling. Overall, our studies reveal a 
novel and complex role for Etv6 in the hematopoietic system that goes beyond the cell-intrinsic role in the 




The Monocyte Compartment 
 Monocytes are highly plastic mononuclear phagocytes that originate from the bone marrow and 
are found mainly in the blood and spleen. Historically, circulating monocytes have been considered 
precursor cells that differentiate into tissue-resident macrophages and DCs. But several studies over the 
years have challenged this generalization; adult tissue macrophages develop before definitive 
hematopoeisis during embryogenesis and can self renew in situ170, while steady-state DCs are not of 
monocyte-origin171.  On the other hand, it is clear that monocytes can and do differentiate into 
macrophages and DCs under inflammatory and pathogenic conditions. Nevertheless, increasing evidence 




 During adult hematopoiesis, monocytes originate and develop in the bone marrow. Seminal 
studies that took place more than 30 years ago laid the foundation for the classical model of monocyte 
development: the first committed progenitor is the monoblast, which gives rise to the pro-monocyte, which 
finally gives rise to the monocyte172-174. Since then, studies within the last decade have updated this 
model with the characterization of a macrophage/dendritic cell progenitor (MDP), the dedicated progenitor 
to the monocytic lineage and (debatably) the DC lineage14,175. This MDP has been shown to give rise to 
the more restricted monocyte progenitor, the common monocyte progenitor (cMoP)176. Using adoptive 
transfer studies, the cMoP has been shown to give rise to both “classical” Ly6Chi and “nonclassical” 
Ly6Clo monocytes, which are released into circulation from the bone marrow and cease to proliferate. It 
has been proposed that the MDP and cMoP together make up subpopulations of the classical 
monoblasts176. Accumulating evidence suggests that Ly6Chi monocytes can differentiate into Ly6Clo 
monocytes in circulation, portraying a more linear stage of development rather than parallel170,177. 
 
Monocyte subsets and function 
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 Development and survival of monocytes require signaling through colony-stimulating factor 1 
(CSF1 or M-CSF) and its receptor M-CSFR (CD115)178-180. Accordingly, all monocytes can be readily 
identified by expression of the receptor for M-CSF, M-CSFR (CD115), in addition to CD11b.  As 
mentioned above, blood monocytes can be categorized into two groups: the “classical” inflammatory 
Ly6Chi monocytes, and “nonclassical” macrophage-like Ly6Clo monocytes. In addition to Ly6C, classical 
monocytes express CCR2 which is required for their release into the periphery, and express intermediate 
levels of CX3CR1181,182. On the other hand, nonclassical Ly6Clo monocytes do not express CCR2 and 
express high levels of CX3CR1181. In addition, nonclassical monocytes can be distinguished from their 
Ly6Chi counterparts by the expression of CD43183. Importantly, defined monocyte subsets within the 
murine model have characteristically analogous counterparts in humans. Ly6Chi monocytes most 
resemble human CD14+ monocytes, which also express CCR2 and low levels of CX3CR1181,184,185. 
Meanwhile, Ly6Clo monocytes most resemble human CD16+ CD14lo monocytes, which show low levels of 
CCR2 and high levels of CX3CR1181,184,185.  
 Classical Ly6Chi monocytes circulate in the blood and are readily recruited to sites of inflammation 
or infection. They have very short half-lives of only about 20 hours170. Once extravasated, they 
differentiate into macrophages and DCs, depending on the non-steady state context. For example, 
infection with Listeria monocytogenes induces monocytes to differentiate into inflammatory DCs, also 
known as Tip-DCs, that secrete TNF" and iNOS186. On the other hand, infection with Toxoplasma gondii 
drives monocytes to differentiate into macrophages187.  
 Nonclassical Ly6Clo monocytes are a distinct subset of monocytes that seem to have divergent 
roles from its Ly6Chi counterparts. Using intravital microscopy, researchers have been able to show that 
Ly6Clo monocytes crawl along the luminal side of blood vessels, and are hypothesized to patrol the 
vascular endothelium microenvironment for any signs of injury or infection in the steady state188. 
Moreover, in cases like Listeria infection and muscle necrosis, Ly6Clo monocytes acquired late in the 
infection or injury seem to exhibit properties that most resemble M2-macrophages, which promote 
resolution of the inflammation, rather than its initiation188-190. These Ly6Clo monocytes were originally 
termed “resident” monocytes because of their persistence in uninflamed and inflamed tissues after 
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adoptive transfer181. Indeed, compared to Ly6Chi monocytes, nonclassical monocytes have an estimated 




 Etv6/Tel belongs to the Ets family of transcription factors, one of the largest families of 
transcriptional regulators found within metazoans191. As the family name suggests, all members contain 
the highly conserved Ets domain, which confers its DNA binding activity. In addition to the Ets domain, 
Etv6 also contains the well-conserved HLH or pointed domain, which provides its protein binding activity 
for homodimeric or heterodimeric interactions191, as well as an autoinhibitory region downstream of the 
Ets domain that blocks its DNA binding surface192. Etv6 is a transcriptional repressor, making it the only 
Ets family repressor found in human malignancies193. 
 
Etv6 in cancer 
ETV6 was originally discovered as part of a chromosomal aberration associated with human 
chronic myelomonocytic leukemia194. Since then, ETV6 has been discovered to be a frequently 
rearranged gene in several hematopoietic malignancies with over 40 associated translocations 
reported195. These commonly include the formation of a chimeric protein containing the pointed domain of 
Etv6 fused to protein tyrosine kinases (e.g. ETV6-ABL1), or DNA binding domains of other transcription 
factors like ETV6-RUNX1, which is the most common fusion gene found in pediatric B cell lymphoblastic 
leukemia195. Furthermore, mutations have also been reported in the rare blastic plasmacytoid neoplasm 
and more recently in familial cases of thrombocytopenia196,197. 
 
Expression and function within the hematopoietic system 
While Etv6 is broadly expressed in many tissues, it is more selectively expressed among cell 
types within the hematopoietic compartment, with the most prominent expression in the HSC 
compartment132,198. Germline deletion of Etv6 in murine models show impaired angiogenesis in the yolk 
sac as well as impairment in bone marrow hematopoiesis199. Accordingly, deletion in adult HSCs show 
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impairments in HSC survival and repopulating activity, whereas in downstream lineages like B cells, T 
cells, and erythroid cells, Etv6 is dispensable. The role and expression of Etv6 in HSCs therefore may 
partially explain its prominence in leukemia.  
Ets factors play important roles in cell fate decisions across species and tissues. In Drosophila, 
for example, Ets transcriptional repressor Yan, the closest ortholog to Etv6, was initially shown to regulate 
the differentiation of neurons in the developing eye, and later found to regulate differentiation in a number 
of additional processes200,201. Within the murine hematopoietic compartment, PU.1 is a major regulator of 
the lymphoid and myeloid lineage, SpiB has been implicated to play a role in pDC development, and Ets1 
has important contributions for plasma cell differentiation and T cell development151,202. The role of Etv6 in 
cell fate decisions has also been demonstrated within the hematopoietic system, as overexpression of 
Etv6 seems to promote TH17 differentiation203.  
Interestingly, Etv6 is also highly expressed in all splenic DC populations as well murine blood 
monocytes132 and human DCs161,162, however its role in these populations still remains to be elucidated. 
Given the precedent role of Ets factors in cell fate decisions, and the correlated expression pattern of 
Etv6 with Flt3 (Figure 2.1), we hypothesized that Etv6 may regulate a developmental transcription 
program within the DC compartment, and possibly the monocyte compartment. Here, we present data of 





Mice deficient for Etv6 show impaired development of bone marrow pDCs and splenic CD8+  cDCs 
Mice that harbor germline deletions of Etv6 show severe impairment in yolk sac angiogenesis and 
therefore the deletion is embryonic lethal198. To study Etv6 in the adult mouse, we bred mice that 
harbored a lox-P-flanked (floxed) allele of Etv6 to a mouse strain that expressed a tamoxifen-inducible 
Cre-ERT2 recombinase protein under the control of the ubiquitous, endogenous Rosa26 promoter. 
Administration of tamoxifen allows temporal deletion of exon 7 of Etv6, which encodes a crucial 
component of the DNA binding domain. Analysis of splenic DC populations after deletion in these mice 
(R26-Etv6!) showed a minor decrease in frequency in cDCs but not splenic pDCs (Figure 3.1A-D). In 
contrast, pDC populations in the bone marrow were reduced by about half in absolute numbers (Figure 
3.1C-D).  
A closer look at cDC subsets showed that the overall decrease in cDC frequency was due to the 
specific decrease in the CD8+ cDC populations, which comprise canonical DEC205+ cDCs and non-
canonical DEC205- cDCs (Figure 3.2A-B). In R26-Etv6! mice, both CD8+ populations showed a decrease 
in both frequency and absolute numbers (Figure 3.2B). Meanwhile, neither the Notch2-dependent Esamhi 
nor Notch2-independent Esamlo CD11b+ cDC subsets showed any difference in numbers within the 
spleen (Figure 3.2B).  
We also investigated whether this developmental phenotype could be recapitulated in vitro. To 
this end, we cultured whole bone marrow from R26-Etv6! mice in Flt3L-containing supernatant to drive 
DC development.  Consistent with what we see in vivo, Etv6-deficient bone marrow yielded significantly 
less CD24+ (CD8+-like) cDCs and pDCs, whereas CD11b+ cDC numbers were not significantly altered 
(Figure 3.3). Overall, these data suggest that ubiquitous deletion of Etv6 during adult hematopoiesis leads 
to an impairment of DC development, particularly in the development of CD8+ cDCs and pDCs. 
 To analyze whether this developmental phenotype occurs early or late in DC development, we 
crossed our Etv6 floxed mice to a mouse strain carrying a transgene of Cre recombinase expressed 
under the control of the CD11c promoter. This deleter strain, termed CD11c-Cre, deletes late in DC 
development after the common DC progenitor (CDP) stage, and in mature DCs. To improve deletion 
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efficiency, we crossed the CD11c-Cre strain to floxed mice that were heterozygous for the excised (null) 
Etv6 allele, identified as CD11c-Etv6!/-. Similar to what was seen in the R26-Etv6!, CD11c-Etv6!/- mice 
showed reduced pDC numbers in the bone marrow, and no change in CD11b+ cDC subset numbers were 
observed (Figure 3.4A-B). In contrast to what was seen in R26-Etv6! DCs, CD8+ cDC subsets showed a 
specific reduction in DEC205- cDCs and not DEC205+ cDCs. In vitro bone cultures showed a similar 
reduction in cell numbers of CD24+ cDCs and pDCs, but to a much lesser extent than seen in ubiquitous 
deletion of Etv6 (Figure 3.5A-C). Based on this data, it appears that Etv6 acts late in DC development to 
support the generation of DEC205- cDCs and pDCs, while it acts earlier to support the generation of 
DEC205+ cDCs.  
 Given the consistent decrease of DEC205- cDCs, we further asked whether or not Etv6 played a 
role in the survival and maintenance of these cells, rather than the development. To test this, we crossed 
our Etv6 floxed mice to a mouse strain expressing a tamoxifen-inducible CreER and YFP cassette, both 
under the control of the endogenous CX3CR1 promoter. Since DEC205- cDCs as well as Esamlo cDCs 
express high levels of CX3CR1 (Figure 3.10A), we could induce deletion of Etv6 in these cells and 
analyze the effect shortly after deletion, before any DC precursors (like the CX3CR1 expressing CDP or 
pre-DC) could completely replenish the pool. We found that treated Cx3cr1-CreER+/- Etv6fl/fl mice (Cx3cr1-
Etv6!) resulted in a slight decrease in overall cDCs (Figure 3.6A), which was mainly caused by the 
decrease in cDCs that only expressed CX3CR1, namely DEC205- and Esamlo cDCs (Figure 3.6B). In 
contrast, pDCs and DEC205+ cDCs, which express low amounts of CX3CR1, were not affected as they 
were with CD11c-Etv6!/- and R26-Etv6! deletion, confirming that potential Etv6-deficient precursors did 
not fully give rise to these cells. These results suggest that Etv6 may play a role in the maintenance and 
survival of DEC205- and Esamlo cDCs.  
   
cDCs deficient for Etv6 show an altered cell surface phenotype  
 While ubiquitous deletion of Etv6 did not result in a significant decrease in all DC numbers, closer 
analysis of the DC subtypes showed an altered cell surface phenotype. In particular, both CD8+ cDC 
subsets showed a reduction in cell surface expression of CD8" (Figure 3.2C-D), most notably in 
DEC205+ cDCs, which normally express very high levels compared to DEC205- cDCs. In addition, Esamhi 
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CD11b+ cDCs showed a slight reduction in proportion as well as an increase in cell surface expression of 
CD11b (Figure 3.2E-F). Esamlo cDCs also showed an increase in CD11b expression to a similar extent 
(Figure 3.2E-F). These results suggest that Etv6 may not only play a role in DC development, but it may 
also affect the differentiation of these DCs. To test this notion, we more closely analyzed the cell surface 
markers of mature DC populations in CD11c-Etv6!/- mice. Analysis of splenic cDC populations showed 
similar phenotypes in CD8+ cDC subsets and CD11b+ cDC subsets, namely the decrease in CD8" 
expression in the former (Figure 3.4C), and the decreased proportion and increased CD11b expression in 
the latter (Figure 3.4D). In addition, in vitro cultures of CD11c-Etv6!/- showed an abnormal increase in 
CD11b expression in CD24+ cDCs (Figure 3.5D). Overall, the alteration in cell surface phenotype in both 
early deletion and late deletion of Etv6 suggest that Etv6 may also play a role in cDC differentiation in 
addition to DC development. Interestingly, the deletion of Etv6 in CX3CR1-expressing DCs did not show 
any change in cell surface expression (Figure 3.6C-D), suggesting that Etv6 may play a role specifically 
regulating the quality of DEC205+ and Esamhi cDCs, and not their CX3CR1 counterparts. 
 
Monocytes deficient for Etv6 show a subtle impairment in homeostasis 
 Because Etv6 is also highly expressed within the monocyte compartment, we investigated how 
deletion of Etv6 affected monocyte development.  CD115+ monocytes can be categorized into two 
groups: classical inflammatory Ly6Chi and the nonclassical patrolling Ly6Clo monocytes. Both subsets 
express CX3CR1, with nonclassical Ly6Clo monocytes expressing the highest levels (Figure 3.10). Thus, 
we analyzed monocyte subsets in our Cx3cr1-Etv6! mice. The flow cytometric staining profile of 
monocyte subsets are shown in Figure 3.7A. We found that deletion of Etv6 in the monocyte 
compartment led to a decrease in both subsets in absolute numbers but not significantly in frequencies in 
bone marrow (Figure 3.7B; data not shown). In the periphery, Cx3cr1-Etv6! deletion mostly affected the 
Ly6Clo population (Figure 3.7B-C). To see if Etv6 deletion affected early progenitors, we analyzed the 
recently described cMoP populations in the bone marrow, which also express CX3CR1176. A 
representative gating strategy is shown in Figure 3.8A. Deletion of Etv6 in the cMoP showed no 
difference in numbers (Figure 3.8B), suggesting that Etv6 does not affect monocytes at the early 
monocyte progenitor stage, and therefore may affect maintenance and homeostasis. 
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Mice deficient for Etv6 show increased Sca1 expression on multiple immune cells 
 Analysis of the most primitive hematopoietic progenitors like HSCs in R26-Etv6! mice was 
confounded by the occasional observation that c-Kithi Sca1- erythromyeloid progenitors showed increased 
expression of Sca1 (data not shown). Sca1 induction in myeloid progenitors was inconsistent likely due to 
the inefficient deletion of the Etv6 allele and/or the rapid selection for non-deleters in this proliferative 
population, as prominence of the floxed allele assessed by PCR was correlated with lack of Sca1 
induction (data not shown). Nevertheless, analysis of downstream mature B cells both in the bone 
marrow and spleen showed slight and consistent increases in Sca1 expression (Figure 3.9). Since Sca1 
is an interferon-responsive gene204, we speculated that these mice may be exhibiting signs of interferon 
signaling. While many cells produce interferon, pDCs are especially adept at producing massive amounts 
of type I interferon. To this end, we analyzed B cells of CD11c-Etv6!/- mice to see if this same Sca1 
induction occurred when Etv6 was deleted in DCs, particularly pDCs. As seen in Figure 3.9B, no Sca1 
induction was observed in B cells, suggesting that DCs are not the source of the interferon production. 
Since Etv6 is also highly expressed in monocytes, and deletion of Etv6 in the monocyte compartment 
does have an effect on the compartment, we also investigated whether monocytes were involved in the 
Sca1 induction. Surprisingly, deletion of Etv6 in CX3CR1-expressing cells led to a robust induction of 
Sca1 induction in early myeloid progenitors (Figure 3.8C) and B cells (Figure 3.9C) as seen with 
ubiquitous deletion of Etv6, in addition to other hematopoietic populations known not to express CX3CR1, 
like granulocytes (Figure 3.9D-G). Interestingly, monocytes consistently showed one of the highest 
changes in Sca1 expression in the bone marrow, spleen and blood compared to other cell types (Figure 
3.9E-G). Overall, these experiments suggest that Etv6 may be controlling the secretion of interferon in a 
CX3CR1-expressing cell.   




The role of Etv6 in early and late DC development 
Ubiquitous deletion and CD11c-Cre deletion both led to the reduction of pDCs and CD8+ cDCs in 
vivo and in vitro, though the CD11c-Cre deletion only affected the DEC205- cDC population in vivo and 
the in vitro phenotype was significantly more mild. The difference in the reduction of CD8+ cDCs between 
ubiquitous deletion and CD11c-Cre deletion may reflect the dual effect of Etv6 on both early and late DC 
development. R26-Etv6! mice delete in both DC progenitors and mature DCs, and the effect on the 
progenitor pool would explain the almost complete depletion of pDCs and CD8+ cDCs in vitro, and the 
broad reduction in pDCs, DEC205-, and DEC205+ cDC in vivo. On the other hand, continued expression 
of Etv6 late in development may also affect the maintenance of pDCs and DEC205- cDCs specifically, 
and thus explain the persistence of DEC205+ cDCs in late deletion. Consistent with this, CX3CR1-
expressing DCs, like DEC205- cDCs, also showed slight reduction in numbers very soon after deletion. 
Evidence in vivo would suggest that the slight reduction of CD24+ cDCs is reflective of the specific 
depletion of in vitro DEC205- counterparts. In support of this, bone marrow cultures derived from Batf3-/- 
mice, which are devoid of DEC205+ cDCs, do still develop variable amounts of residual CD24+ cDCs 
(unpublished data), suggesting that these non-canonical DEC205- cDCs can develop in vitro. 
Interestingly, the dual effect on CD8+ cDCs and pDCs is reminiscent of Irf8 deletion, in which both cell 
types are completely depleted from several lymphoid tissues147. However, the phenotype that we see is 
much less severe, and only seems to effect pDCs in the bone marrow.   
 Even though CD11c-Etv6!/- mice did not show quantitative differences in DEC205+ cDC or 
CD11b+ cDC populations, the significant difference in cell surface phenotype in these cells suggest that 
they are still altered qualitatively by the lack of Etv6. Both subsets of CD8+ cDCs showed a reduction in 
CD8" expression, which was much more severe in DEC205+ cDCs. At the same time, Esamhi and Esamlo 
cDCs showed an increase in CD11b expression, with a very subtle reduction in the proportion of Esamhi 
cDCs. On the surface, it appears that DEC205+ and Esamhi populations are converting to their CX3CR1-
expressing counterparts, as DEC205- cDCs already show low levels of CD8" expression and similarly 
Esamlo populations show high levels of CD11b expression. Further studies are clearly required to confirm 
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this notion, specifically with functional studies of T cell priming as well as genome-wide expression 
analysis. Overall, it seems that Etv6 has multiple roles in development, homeostasis, and differentiation 
across the different DC subtypes. 
 
The role of Etv6 in monocyte homeostasis 
 Among hematopoietic cells, CX3CR1 can be detected on subsets of DC populations, a very small 
proportion of NK cells, and most prominently in the monocyte compartment117. To this end, we used 
Cx3cr1-CreER to delete Etv6 more specifically in the monocyte compartment and evaluate the effect on 
their development. Deletion of Etv6 showed a subtle reduction in the absolute cell numbers in both types 
of monocytes in the bone marrow, whereas deletion in the periphery mostly affected Ly6Clo monocytes. 
Early progenitors of monocytes include the MDP and the cMoP, both of which express moderate levels of 
CX3CR1, and therefore should have also deleted Etv6. Even though analysis was done soon after the 
deletion of Etv6 (5 days), monocytes are a very-short lived cell type and we would expect that any 
developmental defect originating from progenitors would present itself in the mature compartment within 
this time period. Analysis of the precursor cMoP population showed no difference in absolute numbers, 
suggesting that Etv6 functions on the mature monocyte level and that the reduction in numbers is due to 
a defect in homeostasis. However, this does not preclude the possibility that Etv6 may effect monocyte 
development at a more primitive level than the MDP or cMoP. Furthermore, Ly6Chi monocytes have been 
proposed to be precursors to Ly6Clo monocytes in the blood, so further experiments are necessary to 
dissect the differentiation potential of Etv6-deficient Ly6Chi monocytes into Ly6Clo. Nevertheless, the 
results from Cx3cr1-Etv6! analyses suggest that Etv6 functions in the monocyte compartment as well. 
 
The role of Etv6 in regulating interferon signaling 
 The most striking phenotype of the deletion of Etv6 was the induction of Sca1 expression in 
multiple hematopoietic cell types. Interestingly, Sca1 induction was consistently seen in Cx3cr1-Etv6! 
mice. More importantly, non-CX3CR1 expressing cells like B cells showed a significant induction of Sca1 
expression, suggesting a cell-extrinsic effect from a CX3CR1-expressing cell. Mature cell types that 
prominently express CX3CR1 include monocytes, DCs and a small subset of NK cells. Given that Sca1 
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induction was not observed in CD11c-Etv6!/- mice, the most likely candidate for the cytokine source is 
monocytes. In support of this, monocytes consistently showed one of the highest levels of Sca1 induction 
in all tissues analyzed. We cannot rule out the possibility that NK cells may be a source of interferon 
induction as well, however their minimal presence compared to monocytes argues otherwise. Sca1 
induction was only occasionally seen in R26-Etv6! mice, likely due to the inefficiency of allele deletion 
(data not shown) and the selective pressure coming from the HSC compartment to maintain Etv6 
expression, which has been described before199. Given the timing of analysis, it may be possible that non-
deleters may have infiltrated more downstream compartments, especially those that have high turnover 
like monocytes, and attenuated the transient interferon response. Quantitative analysis of Etv6 
expression within individual cell populations would confirm this notion. Nevertheless, these results 
suggest that Etv6 may be a negative regulator of interferon production. In line with this, the interaction of 
Ets factors and interferon regulating factors has precedence. For example, Spi1/PU.1 has been shown to 
interact with Irf4 and Irf8 and induce transcription of interferon genes205. Interestingly, Etv6 has also been 
proposed to interact with Irf8 and repress transcription at interferon response elements through the 
recruitment of a histone deacetylase206. Confirmation of the interferon signature and pinpointing the exact 
cell source of interferon secretion is currently under active investigation. Future studies establishing the 
functional implications of this signaling are warranted. 
 
 Overall, the studies presented in this chapter identify Etv6 as a potential multi-faceted regulator in 
DC and monocyte development, homeostasis and/or function. Using several models of conditional 
deletion, we have shown that Etv6 developmentally affects pDCs and CD8+ cDCs, and potentially affects 
the homeostasis and differentiation of several cDC subsets. We have also provided evidence for a role of 
Etv6 in monocyte homeostasis, selectively in Ly6Clo monocytes, as well as uncovered a potential role for 
Etv6 in the repression of interferon signaling. Elucidation of these features will provide key insight on 
potentially new mechanisms regulating DC and monocyte homeostasis and function. 
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MATERIALS AND METHODS 
 
Animals 
Etv6fl/fl were a kind gift from H. Hock199. R26-CreER mice were a kind gift from T. Ludwig207. Itgax-Cre 
(CD11c-Cre) was developed in our lab143. Cx3cr1-CreER208 mice were acquired from Jackson. All mice 
were on C57BL/6 background. All animal studies were performed according to the investigator’s protocol 
approved by the Institutional Animal Care and Use Committee of Columbia University. 
 
Cell preparations 
Spleens were minced and digested with collagenase D (1 mg/mL) and DNaseI (20µg/mL) in for 30-60 min 
at 37°C. Tissues were pressed through a nylon cell strainer to yield single cell suspensions and then 
subjected to red blood cell (RBC) lysis before being filtered. Bone marrow was prepared by flushing 
femurs and tibias with phosphate buffer saline (PBS) using a 27-gauge needle before RBC lysis. Blood 
was acquired by cardiac puncture and subject to RBC lysis. 
 
Flow cytometry 
Cells were stained with the following fluorochrome- or biotin-conjugated antibodies from eBioscience or 
as indicated: anti-CD11c (N418), MHC II (M5/114.15.2), CD11b (M1/70), CD8! (53-6.7), DEC205 (NLDC-
145; BioLegend), Esam (IG8), B220 (RA3-6B2), mPDCA-1/Bst2 (Miltenyi Biotec), CD317/PDCA/Bst2 
(Biolegend clone 927), CD24 (M1/69), Ly6C (HK1.4), Ly6G (IA8), F4/80 (BM8), NK1.1 (PK136), Ter119 
(TER-119), CD49b (DX5), TCR" (H57-597), CD3 (17A2), Flt3 (A2F10), c-Kit (2B8), Sca-1 (D7), and 
CD115 (AFS98).  Cell acquisition was done on LSR II (BD Biosciences) using FACSDiva (BD 
Biosciences) and analysis was done on FlowJo (Tree Star).  
 
In vitro BM-derived DC cultures 
Bone marrow cells were harvested as described above. RBC-lysed cells were plated in triplicates in a 24-
well plate at 2 x 106 per well in DMEM/10% FCS and 20% supernatant from cultured Flt3L-secreting B16 
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melanoma cell lines. Suspension and adherent cells were harvested after 8 days and triplicates were 
pooled for counting and flow cytometric analysis. 
 
Tamoxifen treatment 
Mice were treated by oral gavage for three consecutive days with 5 mg of tamoxifen suspended in 
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Figure 3.1. Ubiquitous deletion of Etv6 shows a decrease in bone marrow pDCs. 
R26-CreER+/- Etv6+/+ or Etv6fl/fl (Ctrl) and R26CreER+/- Etv6fl/fl (R26-Etv6!) were treated with 5 mg of 
tamoxifen by oral gavage for 3 consecutive days. Mice were sacrificed 9 days after the last treatment. 
(A)  Representative staining profiles of splenic cDC populations. Numbers in plots indicate percent 
of gated population.   
(B)  Absolute numbers (top) and frequencies (bottom) of total cDCs as identified in (A) (mean ± 
SD, n = 4-5).  
(C)  Representative staining profiles of pDC populations in spleen (SPL) and bone marrow (BM).   
(D)  Absolute numbers (top) and frequencies (bottom) of pDCs as identified in (C) (mean ± SD, n = 
4-5).  



























































































































































































Figure 3.2. Ubiquitous deletion of Etv6 shows a decrease in CD8+ cDCs and alterations in cDC 
cell surface phenotype. 
R26-CreER+/- Etv6+/+ or Etv6fl/fl (Ctrl) and R26CreER+/- Etv6fl/fl (R26-Etv6!) were treated with 5 mg of 
tamoxifen by oral gavage for 3 consecutive days. Mice were sacrificed 9 days after the last treatment. 
(A)  Representative staining profile cDC subsets pre-gated on CD11chi MHCII+. Numbers in plots 
indicate percent of gated population. 
(B)  Absolute numbers (top row) and frequencies (bottom row) of cDC subsets as identified in (A) 
(mean ± SD, n = 4-5). 
(C)  Representative histograms of CD8" expression in CD8+ cDC subsets. Dotted line shows 
means fluorescent intensity (MFI) of CD8" expression in Ctrl DEC205+ cDCs. 
(D)  MFI of CD8" expression as depicted in (C) (mean ± SD, n = 4-5). 
(E)  Representative histograms of CD11b expression in CD11b+ cDC subsets. Dotted line shows 
MFI of CD11b expression in Ctrl Esamhi cDCs. 
(F)  MFI of CD11b expression (left) as depicted in (E) and percent of Esamhi cDCs out of total 
CD11b+ cDCs (right) as depicted in (A) (mean ± SD, n = 4-5). 
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Figure 3.3. Etv6-deficient mice show impairment in Flt3L-driven DC development in vitro.  
R26-CreER+/- Etv6+/+ or Etv6fl/fl (Ctrl) and R26CreER+/- Etv6fl/fl (R26-Etv6!) were treated with 5 mg of 
tamoxifen by oral gavage for 3 consecutive days. Mice were sacrificed 9 days after the last treatment. 
Whole bone marrow from treated mice was cultured in 20% Flt3L-rich supernatant for 7 days.  
(A)  Representative staining profiles of cDC subsets pre-gated on CD11c+ MHCII+. Numbers on plot 
indicate fraction of cells within gated population.  
(B)  Representative staining profiles of pDC subsets pre-gated on B220+ cells. Numbers on plot 
indicate fraction of cells within gated population.  
(C)  Absolute numbers of DC populations identified as in (A-B)(mean ± SD, n = 4-5). 
Statistically significant differences are indicated as:!* p < 0.05 ; ** p < 0.01 ; *** p < 0.001 
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Figure 3.4. DC-specific deletion of Etv6 results in a mild decrease in DEC205- CD8+ cDCs and 
pDCs, and alters cDC phenotypes. 
(A)  Absolute numbers (top row) and frequencies (bottom row) of DCs as identified in (Fig. 3.1A,C) 
in Etv6fl/fl (Ctrl) and CD11c-Cre+/- Etv6fl/- (CD11c-Etv6!/-) mice (mean ± SD, n = 4).  
(B)  Absolute numbers (top row) and frequencies (bottom row) of cDC subsets as identified in (Fig.
3.2A) in Ctrl and CD11c-Etv6!/- mice (mean ± SD, n = 4).  
(C)  Mean fluorescent intensity (MFI) of CD8" expression as depicted in (Fig. 3.2C) in Ctrl and 
CD11c-Etv6!/- mice (mean ± SD, n = 4). 
(D)  MFI of CD11b expression (left) as depicted in (Fig. 3.2E) and percent of Esamhi cDCs out of 
total CD11b+ cDCs (right) as depicted in (Fig. 3.2A) (mean ± SD, n = 4). 

























































































































































































































































































































Figure 3.5. Deletion of Etv6 late in DC development shows a subtle impairment of Flt3L-driven 
DC development and alters CD24+ cDCs in vitro. 
Whole bone marrow from Etv6fl/fl (Ctrl) and CD11c-Cre+/- Etv6fl/- (CD11c-Etv6!/-) mice was cultured in 
20% Flt3L-rich supernatant for 7 days.  
(A)  Representative staining profiles of cDC subsets pre-gated on CD11c+ MHCII+. Numbers on plot 
indicate fraction of cells within gated population.  
(B)  Representative staining profiles of pDC subsets pre-gated on B220+ cells. Numbers on plot 
indicate fraction of cells within gated population.  
(C)  Absolute numbers of DC populations identified as in (A-B) (mean ± SD, n = 3). 
(D)  Representative histograms of CD11b expression on CD24+ cDCs. Bar graph shows mean 
fluorescent intensity (MFI) of CD11b expression (mean ± SD, n = 3). 



































































































































Figure 3.6. Deletion of Etv6 in CX3CR1-expressing cells results in a mild decrease in DEC205- 
CD8+ and Esamlo CD11b+ cDCs. 
Etv6fl/fl (Ctrl) Cx3cr1-CreER+/- Etv6fl/fl (Cx3cr1-Etv6!) were treated with 5 mg of tamoxifen by oral 
gavage for 3 consecutive days. Mice were sacrificed 5 days after the last treatment. 
(A)  Absolute numbers (top row) and frequencies (bottom row) of DCs as identified in (Fig. 3.1A-B) 
(mean ± SD, n = 6).  
(B)  Absolute numbers (top row) and frequencies (bottom row) of cDC subsets as identified in (Fig.
3.2A) (mean ± SD, n = 6).  
(C)  Mean fluorescent intensity (MFI) of CD8" expression as depicted in (Fig. 3.2C) (mean ± SD, n 
= 6). 
(D)  MFI of CD11b expression (left) as depicted in (Fig. 3.2E) and percent of Esamhi cDCs out of 
total CD11b+ cDCs (right) as depicted in (Fig. 3.2A) (mean ± SD, n = 6). 
Statistically significant differences are indicated as:!* p < 0.05 ; ** p < 0.01 ; *** p < 0.001 
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Figure 3.7. Deletion of Etv6 in CX3CR1-expressing cells results in slight reduction in bone 
marrow and peripheral monocytes. 
Etv6fl/fl (Ctrl) Cx3cr1-CreER+/- Etv6fl/fl (Cx3cr1-Etv6!) were treated with 5 mg of tamoxifen by oral 
gavage for 3 consecutive days. Mice were sacrificed 5 days after the last treatment. 
(A)  Representative staining profile Ly6Chi and Ly6Clo monocytes in the bone marrow. Similar 
gating strategies were used to quantify monocytes in the spleen and blood. Lineage markers 
include Ly6G, CD49b, B220, and CD3. 
(B)  Absolute numbers of Ly6Chi, Ly6Clo, and granulocytes in bone marrow (BM) and spleen (SPL). 
Granulocytes were identified as Lineage(Ly6G)+ CD11b+ FSChi SSChi (mean ± SD, n = 6). 
(C)  Frequency of Ly6Clo monocytes in blood (mean ± SD, n = 6) 











































































































































































































































Figure 3.8. Deletion of Etv6 in CX3CR1-expressing does not change cMoP numbers but 
induces Sca1 expression on stem/progenitor populations. 
Etv6fl/fl (Ctrl) and Cx3cr1-CreER+/- Etv6fl/fl (Cx3cr1-Etv6!) were treated with 5 mg of tamoxifen by oral 
gavage for 3 consecutive days. Mice were sacrificed 5 days after the last treatment. 
(A)  Representative gating strategy for common monocyte progenitors (cMoPs) in bone marrow. 
Lineage markers include Ly6G, CD11c, CD49b, B220, TCRb, and Ter119. 
(B)  Absolute numbers of cMoPs in the bone marrow (mean ± SD, n = 6). 
(C)  Representative staining profiles of Lin- Ly6C- CD11b- cells in bone marrow and histograms of 
gated populations showing Sca1 expression. 
Statistically significant differences are indicated as:!* p < 0.05 ; ** p < 0.01 ; *** p < 0.001 
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Figure 3.9. Deletion of Etv6 in CX3CR1-expressing cells results in global Sca1 induction. 
(A)  Mean fluorescent intensity (MFI) of Sca1 expression in mature B cells in R26-CreER+/- Etv6+/+ 
or Etv6fl/fl (Ctrl) and R26CreER+/- Etv6fl/fl (R26-Etv6!) spleen (SPL) and bone marrow (BM)
(mean ± SD, n = 4-5). Mice were treated with 5 mg of tamoxifen by oral gavage for 3 
consecutive days and analyzed 9 days after last treatment. B cells were identified as B220+ 
MHCIIhi. 
(B)  MFI of Sca1 expression in mature B cells in Etv6fl/fl (Ctrl) and CD11c-Cre+/- Etv6fl/- (CD11c-
Etv6!/-) SPL and BM (mean ± SD, n = 4). B cells were identified as B220+ MHCIIhi. 
For C-G, Etv6fl/fl (Ctrl) and Cx3cr1-CreER+/- Etv6fl/fl (Cx3cr1-Etv6!) mice were treated with 5 mg of 
tamoxifen by oral gavage for 3 consecutive days and analyzed 5 days after last treatment. B cells 
were identified as B220+ MHCIIhi IgD+. 
(C)  MFI of Sca1 expression in mature B cells in SPL and BM (mean ± SD, n = 6).  
(D)  Representative histograms of Sca1 expression in various immune cells in SPL and BM. Cell 
types were identified as follows: granulocytes - Lineage(Ly6G)+ CD11b+ FSChi SSChi; 
monocytes (as in Fig. 3.7A); pDCs (as in Fig. 3.1C); B cells - B220+ MHCIIhi IgD+; cDC subsets 
(as in Fig. 3.2A). 
(E)  Fold change of Sca1 MFI in various immune cells as defined in (D) in SPL. To calculate fold 
change, individual Cx3cr1-Etv6! Sca1 MFIs were normalized to the Ctrl mean MFI for each 
tissue cell type. Dotted line delineates fold change of 1 (mean ± SD, n = 6). 
(F)  Fold change of Sca1 MFI in various immune cells as defined in (D) in BM (mean ± SD, n = 6). 
Fold change was calculated as in (E). c-Kit hi progentiors were defined as in (Fig. 3.8C).  
(G)  Fold change of Sca1 MFI in various immune cells as defined in (D) in blood (mean ± SD, n = 
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Figure 3.10. YFP expression in untreated Cx3cr1-CreER mice. 
(A)  Representative staining profiles of YFP expression in spleen. Cell types were identified as 
follows: granulocytes - Lineage(Ly6G)+ CD11b+ FSChi SSChi; monocytes (as in Fig. 3.7A); 
pDCs (as in Fig. 3.1C); B-cells - B220+ MHCIIhi IgD+; cDC subsets (as in Fig. 3.2A). 
(B)  Representative staining profiles of YFP expression in bone marrow. Cell types were defined as 




Ly6Clo 50.8 monocytes SPL 14
DEC205- SSClo 21.4 cDC2 SPL 14
Esam- 33.3 cDC2 SPL 14
Ly6Chi 40.9 monocytes SPL 14
Esam+ 65.2 cDC2 SPL 14
DEC205+ SSChi 68.3 cDC2 SPL 14
pDC 0.449 pDC SPL 14
FSC hi SSChi 95.9 monocytes SPL 14
mature B-cell 89.4 pDC SPL 14
Gate % Sample
Ly6Clo 6.57 monocytes BM 14
Ly6Chi 90.7 monocytes BM 14
pDC 1.14 pDC BM 14
FSC hi SSChi 98.3 monocytes BM 14








































CONCLUSIONS AND FUTURE DIRECTIONS 
 
The role of immunosurveillance in acute myeloid leukemia: a new perspective 
 Acute myeloid leukemia (AML), like other tumors, is not simply a disease of uncontrolled, cell-
intrinsic cell expansion – it is also a disease of immunodeficiency specific to tumor immunosurveillance. 
The role of the immune system during cancer development has only recently been appreciated as one of 
the hallmarks of cancer101. Pioneering studies using carcinogen-induced tumors established a clear role 
for the immune system in eliminating and shaping cancer development, and since then several studies 
have validated the concept of cancer immunosurveillance100,105,209,210. But while immunosurveillance in 
solid tumors has been well studied, immunosurveillance in hematological tumors has been relatively 
under-explored, especially in leukemia. Moreover, even fewer studies exist that explore the role of DCs in 
the immunosurveillance of leukemia. 
 In this study, we focus on Flt3, an established developmental regulator of the DC lineage. Our 
knowledge of this fundamental pathway paved the way to investigate the effect of its dysregulated 
activation in DC homeostasis and explore the potential consequences on the immune system. We found 
that a prominent form of the mutated receptor, Flt3-ITD, found in AML, causes the expansion of DC 
subsets and supports the modulation of T cell responses, including the increased presence of regulatory 
T cells. Collectively, we offer a new mechanism in which DCs can promote leukemogenesis before the 
clinical manifestations of the disease. Because of their important role in facilitating immune tolerance, the 
DC lineage would be an attractive target for tumor exploitation. Indeed, AML DCs have been described to 
be abnormal and/or dysfunctional, and have also been proposed to affect T cell activity and promote Treg 
induction113-115. But these mechanisms have been restricted to mainly in vitro systems, and to our 
knowledge, no specific mechanisms have been tied to these phenomena in vivo until now.  
Beyond implicating an active role for DCs in leukemogenesis, this work also underlines the 
unique ability of AML mutations in infiltrating the immune system, which prompts a new perspective on 
leukemogenesis. More often than not, mutations involved in immune evasion in AML have been 
described in a similar fashion as in solid tumors, that is, as a separate entity from the immune system 
(Figure 4.1A). For example, relapsed leukemia has been described to downregulate mismatched HLA 
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molecules to avoid cytotoxicity from graft-versus-leukemia effects, and there is an increased frequency of 
AMLs that express inhibitory molecules that promote escape from NK-cell mediated cytotoxicity211,212. 
However, the genetic landscape of AML is quite different from solid tumors, in that relatively few genetic 
mutations are present213. This phenomenon would suggest that prominent AML mutations serve 
additional purposes beyond cell-intrinsic transformation. Because both the leukemia and immune cells 
arise from the same source, AML out of all tumors would have the unique ability to co-opt the immune 
system, requiring the least amount of genetic manipulation if it can target an opportune gene. Specific 
stem/progenitor mutations like the Flt3-ITD mutation, which like many other genetic lesions intrinsically 
promotes the proliferation and survival of the tumor itself, may carry down the mutation to downstream 
immune cells and thereby have a dual role in modulating immunosurveillance (Figure 4.1B). We propose 
that other single mutations found in leukemia likely exist that harbor the same kind of multi-tasking ability 
of intrinsically transforming a cell and disabling immunosurveillance. While our observations on the DC 
lineage and regulatory T cells are specific to the Flt3-ITD mutation, certainly mutations that affect other 
immune cells may support their own strategies of immune evasion. Therefore, future directions require 
the re-evaluation of prominently occurring AML mutations, not just as factors that promote cell-intrinsic 
survival, growth, or proliferation, but also as factors that promote immune modulation. This altered 
perspective may unveil potentially new features of tumor promotion and provide more nuanced 
mechanistic explanations as to why particular mutations are associated with more aggressive disease. It 
is clear that the current standard of broad-spectrum chemotherapy that targets proliferating cells is 
insufficient and obsolete, thus this new perspective will be imperative for developing new therapeutic 
strategies for AML that are tailored for specific subgroups, and thus will highlight the most important 
signaling pathways to target.  
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Figure 4.1. Immune evasion in solid tumors versus leukemias. 
(A)  Tumor cells from solid tumors acquire several mutations that separately promote cell-intrinsic 
transformation and protection from the immune system. Purple cells represent immune cells, 
and black cells with white borders represent tumor cells. Blue bar signifies protection from 
immune elimination. Asterisks signify different mutations. 
(B)  Leukemic cells acquire few mutations that dually promote transformation and protection from 
the immune system at the same time. Purple cells represent immune cells, black cells with 
white border represent leukemic cells, and black cell with purple border represents leukemia-



















Uncovering new mechanisms of DC fate decisions 
 The central role of DCs in facilitating the adaptive immune response prompts a comprehensive 
examination of the basic mechanisms that control their development and function. Their clear functional 
heterogeneity highlights the need to better understand how these subsets develop in order to take 
advantage of this division of labor for therapeutic use. Several questions still remain on the basic 
development of DCs in the steady state, such as which factors specifically control the lineage 
specification of cDCs over pDCs, and the precise mechanism of cDC differentiation. By studying the roles 
of two candidate genes, this thesis work enhances our understanding of cDC development. 
We explored the implication of two transcription factors, Mycl1 and Etv6, in regulating genetic 
programs that would affect DCs in the steady state. Despite its expression specificity in DCs, several lines 
of phenotypic and functional analyses provide support for a negligible role of Mycl1 in the general 
development and function of DCs (Figure 4.2), and raises debate on its recently described role in DC 
function and proliferation. While technical considerations and genetic redundancy may account for the 
disparity, we conclude that cDCs are relatively functional in the absence of Mycl1, and that Mycl1 does 
not influence the development of the cDC lineage. Etv6, on the other hand, shows a more apparent 
influence in DC homeostasis and development. Early on in DC development, it seems to affect the 
development of CD8+ cDCs, and late in DC development, it may continue to play a role in mature pDC 
and cDC commitment, quite possibly function (Figure 4.2). In addition, it may also play a potential role in 
monocyte homeostasis and a functional role as a suppressor of unwarranted cytokine secretion. All of 
these observations are still in their nascent state, so clearly future actions are required to corroborate 
these claims. Functional studies in T cell priming will be required to assess whether the effect of Etv6 on 
mature DCs compromises their identity, while infection models that induce inflammation like Listeria 
monocytogenes will be useful in examining the effector functions of Etv6 monocytes. Furthermore, a more 
comprehensive analysis of the interferon signature will be required, using genome-wide analysis and 
genetic models to elucidate a mechanism. 
Nevertheless, while it is clear that Etv6 may have multiple roles during DC development, this 
promising role of Etv6 in cDC differentiation will provide significant insight on a portion of DC development 
that is not well described. Few transcription factors have been identified as regulators of the late terminal 
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commitment of cDC subsets. These include Batf3, Id2, and Irf8 for CD8+ cDCs, and RelB and Irf4 for 
CD11b+ cDCs. However, these transcription factors selectively affect one cDC subset over the other, and 
currently there is yet to be a common transcription factor that has been described to be important for the 
commitment of both. Bcl6-deficiency has been shown lead to the depletion of both cDC subtypes, 
however it seems to promote the survival of these cells, rather than their commitment214. In contrast, 
deletion of Etv6 late in DC development does not seem to grossly alter the quantity of these cDCs, but 
instead grossly alters the quality of the cDCs as observed by cell surface phenotype, which is a feature 
that already distinguishes it from other transcription factors. The effect on differentiation may ultimately 
have a significant impact on cDC function and identity.  Furthermore, as a member of one of the biggest 
families of transcription factors among metazoans, the study of Etv6 and the nature of other Ets-family 
binding partners throughout DC development may provide a versatile mechanism for which the DC 
lineage could resolve DC fate commitment. Overall, Etv6 remains as a prospective, novel regulator of 
cDC differentiation and function, and the dissection of its regulation will provide key insight on the 
mechanisms of cDC development. 
 
Collectively, the work presented here dissects the normal regulatory mechanisms that govern the 
development of mononuclear phagocytes, with emphasis on DC development. We provide new insight on 
how normal regulatory mechanisms in DC development can be misappropriated for pathological 
conditions such as leukemia. Furthermore, we provide support for a dispensable role of Mycl1 in DC 
development and function, which conflicts with previous findings. Finally, we lay a foundation for an 
uncharacterized role of Etv6 in DC and monocyte homeostasis and the regulation of cytokine signaling. 
Overall, the examination of these basic regulatory mechanisms will advance our understanding of DC 
















Figure 4.2. Summary of the roles of Mycl1 and Etv6 during DC development. 
Questions still remain on what transcriptional factors control the cDC lineage commitment, 
differentiation, and function. This thesis work rules out Mycl1 as an important regulator of overall DC 
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